<ul> <li>future COVID-19 pandemic outcomes</li> <li>Wan Yang<sup>1</sup> and Jeffrey Shaman<sup>2</sup></li> <li><sup>1</sup>Department of Epidemiology, <sup>2</sup>Department of Environmental Health Sciences, Mailman</li> <li>of Public Health, Columbia University, New York, NY, USA</li> </ul>	an School
<sup>1</sup> Department of Epidemiology, <sup>2</sup> Department of Environmental Health Sciences, Mailma	an School
	an School
5 of Public Health, Columbia University, New York, NY, USA	
••••••••	
6 Correspondence to: wy2202@cumc.columbia.edu (WY); jls106@cumc.columbia.ec	u (JS)
7	
8 Abstract	
9 Three SARS-CoV-2 variants classified as variants of concern – B.1.1.7, B.1.351, and P.1 -	- have
10 spread globally. To characterize their viral and epidemiological properties in support of	f public
11 health planning, we develop and apply a model-inference system to estimate the chan	ges in
12 transmissibility and immune escape for each variant, based on case and mortality data	from the
13 country where each variant emerged. Accounting for under-detection of infection, dise	ease
14 seasonality, concurrent non-pharmaceutical interventions, and mass-vaccination, we e	stimate
15 that B.1.1.7 has a 46.6% (95% CI: 32.3 – 54.6%) increase in transmissibility but nominal	immune
escape from protection induced by prior wild-type infection; B.1.351 has a 32.4% (95%	CI: 14.6
17 – 48.0%) increase in transmissibility and 61.3% (95% CI: 42.6 – 85.8%) immune escape;	and P.1
18 has a 43.3% (95% CI: 30.3 – 65.3%) increase in transmissibility and 52.5% (95% CI: 0 – 7	5.8%)
immune escape. Model simulations indicate that B.1.351 and P.1 could supplant B.1.1.	7
20 dominance and lead to increased infections. Our findings highlight the importance of	
21 preventing the spread of B.1.351 and P.1, in addition to B.1.1.7, via continued preventi	ve
22 measures, prompt mass-vaccination of all populations, continued monitoring of vaccin	е
efficacy, and possible updating of vaccine formulations to ensure high efficacy.	
24	
25 Main text	
26 Multiple SARS-CoV-2 variants have been identified since summer 2020. Among these,	
27 variants – namely, B.1.1.7, B.1.351, and P.1 – have been classified as variants of concer	• •
28 per evidence indicating these genotypes are substantially more transmissible, evade p	
29 immunity (either vaccine-induced or conferred by natural infection with wild-type virus	5),
30 increase disease severity, reduce the effectiveness of treatments or vaccines, or cause	
31 diagnostic detection failures. <sup>1,2</sup> Multiple lines of evidence indicate the B.1.1.7 variant i	
32 50% more transmissible than wild-type virus but does not produce antigenic escape. <sup>3-6</sup>	Further,
33 several studies have shown that both the B.1.351 and P.1 variants are resistant to	
34 neutralization by convalescent plasma from individuals previously infected by wild-typ	
35 CoV-2 viruses and sera from vaccinated individuals; <sup>5-9</sup> however, changes to the transm	ssibility
36 of these latter two variants are less well resolved. A better understanding of the	
37 transmissibility and immune escape properties of VOCs – in particular, B.1.351 and P.1	at

38 present – is needed to anticipate future COVID-19 pandemic outcomes and support public

- 39 health planning.
- 40
- 41 In this study, we develop a model-inference system to estimate the relative change in
- 42 transmissibility and level of immune evasion for different SARS-CoV-2 variants, while
- 43 accounting for under-detection of infection, delays of reporting, disease seasonality, non-
- 44 pharmaceutical interventions (NPIs), and vaccination. Testing using model-generated synthetic
- 45 incidence and mortality data indicates this inference system is able to accurately identify shifts
- 46 in transmissibility and immune evasion. We then apply the validated inference system in
- 47 conjunction with incidence and mortality data from the UK, South Africa, and Brazil the three
- 48 countries where VOCs B.1.1.7, B.1.351, and P.1 were first identified, respectively to estimate
- 49 the change of transmissibility and immune evasion for the three VOCs, separately. We further
- 50 use these inferred findings in a multi-variant, age-structured model to simulate epidemic
- 51 outcomes in a municipality like New York City (NYC) where multiple variants, including B.1.1.7,
- 52 B.1.351, and P.1, have been detected.
- 53

## 54 The model-inference system and validation

- 55 We first tested our model-inference system using 10 model-generated synthetic datasets,
- 56 depicting different combinations of population susceptibility prior to the emergence of a new
- 57 variant, changes in transmissibility and immune evasion for the new variant, and infection-
- 58 detection rate. As population susceptibility, interventions, and disease seasonality can all affect
- 59 apparent transmissibility at a given time and in order to focus on variant-specific properties,
- 60 here we defined transmissibility as the average number of secondary infections per primary
- 61 infection, *after removing the effects of these three factors* (see Methods). We then quantified
- 62 the change in transmissibility as its relative increase once the new variant becomes dominant.
- 63 Similarly, we quantify the level of immune evasion as the increase in susceptibility after the
- 64 new variant becomes dominant, relative to prior population immunity from wild-type infection.
- 65

66 Fig. 1 shows example test results comparing model-inference system estimates with model-

- 67 generated 'true' values of transmissibility and susceptibility using an infection-detection rate of
- 68 20%. Across a range of epidemic dynamics, the model-inference system is able to fit both
- 69 weekly incidence and mortality data (Fig. 1A) and estimate the transmissibility and
- susceptibility over time for both the initial pandemic wave and the subsequent pandemic wave
- caused by a new variant (Fig. 1B). In addition, when aggregated over both pandemic waves, the
- 72 model-inference system is able to estimate the relative changes in transmissibility and immune
- 73 evasion due to a new variant (Fig. 1C). When the system is less well constrained (e.g., an
- 74 infection-detection rate of 10%), model estimates, albeit less accurate, still closely track true
- 75 values in most instances (Fig S1).

#### 76

#### 77 Reconstructed pandemic dynamics in the three countries

78 Following the initial emergence of SARS-CoV-2 in early 2020, the UK, South Africa, and Brazil

- 79 experienced very different epidemics (Fig. 2). The model-inference system is able to recreate
- 80 the observed incidence and mortality epidemic curves for all three countries (Fig 2 A, C, and E).
- 81 Further, cross-validation using independent data shows that the model estimates closely match
- 82 measured SARS-CoV-2 prevalence in the UK<sup>10,11</sup> and serology measures of cumulative infection
- rates in South Africa<sup>12,13</sup> and Brazil,<sup>14</sup> respectively (Fig 2 B, D, and F). These results indicate the
- 84 model-inference system accurately estimates the underlying transmission dynamics for all
- 85 three countries.
- 86
- 87 In the UK, a prompt lockdown allowed the country to contain the first pandemic wave (Fig. 3).
- 88 The real-time effective reproduction number  $(R_t)$ , which measures the average number of
- secondary infections at a given point in time, dropped from 2.2 (95% CrI: 1.0 3.9) during the
- 90 week of 3/1/2020 to below 1 during the week of 3/22/2020, the first week of the lockdown (Fig.
- 91 3A). By the week of 6/28/2020 (the week with the lowest incidence following the first
- 92 pandemic wave), 6.4% (95% CrI: 3.6 12.3%) of the UK population are estimated to have been
- 93 infected. However, with the relaxation of intervention measures during the summer,
- 94 transmission gradually increased again (as indicated by the estimated  $R_t > 1$ ), leading to a large
- 95 surge of infections in the autumn of 2020 (Figs 2A-B and 3A). A second lockdown implemented
- 96 in Nov 2020 reduced transmission transiently (*R*<sup>*t*</sup> was below 1 during the 4-week lockdown
- 97 period; Fig 3A). Shortly thereafter widespread transmission of the B.1.1.7 variant led to a
- 98 further increase of cases before this activity was curtailed by a third lockdown and mass-
- 99 vaccination.
- 100
- 101 In South Africa, initial transmission was low likely due to a strong public health response (a 102 lockdown was implemented from 3/26/20 to 4/16/20) and less conducive conditions for 103 transmission during southern hemisphere summer and autumn (Figs 2C, 3D, and S2B). 104 However, as the country relaxed intervention measures and entered the winter, transmission increased substantially from May 2020 onwards, leading to a large pandemic wave during May 105 - Sep 2020. After accounting for under-detection of infection (Fig S3C), consistent with serology 106 data,  $^{12,13}$  the model-inference system estimates that 30.0% (95% CrI: 18.0 – 47.1%) of the 107 108 population had been infected by the week of 9/20/2020 (i.e., the week with the lowest 109 incidence following the first pandemic wave; Fig 2D). After two months with relatively low 110 incidence, the emergence of the B.1.351 variant led to a resurgence of infections in late 2020 111 and a larger second pandemic wave (Fig 3D). By the week of 4/11/21, another 38.6% (95% CrI: 112 24.1 - 61.1%) of the population are estimated to have been infected, including re-infections. 113

- 114 In Brazil, no national lockdown was implemented during the pandemic. A large first pandemic
- 115 wave occurred during Mar Oct 2020 (Figs 2E and 3G). By the week of 11/1/2020 (i.e., the
- week with the lowest incidence following the first wave), 45.7% (95% CrI: 28.4 69.0%) of the
- population are estimated to have been infected (Fig 3F). This estimate includes all infections
- and thus is much higher than the reported number of cases (3.77% of the population; see
- estimated infection-detection rates in Fig S3E). In addition, unlike the UK and South Africa
- 120 where the pandemic wave rose and fell quickly, pandemic activity based on national
- 121 incidence and mortality curves remained at high levels for a much longer duration (Fig. 2E).
- 122 This may be due to the larger geographical area of Brazil, the aggregative nature of country-
- 123 level incidence and mortality data combining multiple outbreak waves from different sub-
- regions of the country, and the lack of national restrictions to curb the pandemic. Despite this
- 125 large first pandemic wave, the emergence of the P.1 variant led to a second large pandemic
- 126 wave from Dec 2020 onwards. Similar traveling waves through the country were evident from
- the incidence curve (Fig 2E). By the week of 4/11/21, an additional 60.7% (95% CrI: 40.5 –
- 128 92.0%) of the population are estimated to have been infected, including re-infections.
- 129

# 130 Estimated increased transmissibility and immune evasion

- 131 Accounting for concurrent NPIs, vaccination and seasonal transmission trends (Fig S2), model-
- 132 inference system estimates also enable assessment of key properties specific to the three
- 133 variants. Estimated transmissibility increased in conjunction with the widespread presence of
- the new variant in each country (Fig 3B for B.1.1.7, 3E for B.1.351, and 3H for P.1). Overall,
- estimated viral transmissibility increased by 46.6% (95% CI: 32.3 54.5%) for the B.1.1.7
- 136 variant, 32.4% (95% CI: 14.6 48.0%) for the B.1.351 variant, and 43.3% (95% CI: 30.3 65.3%)
- 137 for the P.1 variant, compared to the wild-type virus (Table 1). In addition, the model-inference
- 138 system also detects large increases of population susceptibility for the B.1.351 and P.1 variants,
- but not the B.1.1.7 variant (Fig. 3F and 3I vs. 3C; and Table 1). Specifically, the model estimates
- immune evasion for the B.1.351 variant among 61.3% (95% CI: 42.6 85.8%) of the population
- 141 infected with the wild-type virus during the first wave in South Africa and for the P.1 variant
- among 52.5% (95% CI: 0 75.8%) of the population infected with the wild-type virus during the
- 143 first wave in Brazil.
- 144

# 145 **Competition among variants and potential future outcomes.**

- 146 As many places have now detected one or more of the three VOCs locally, it is important to
- 147 understand the potential pandemic outcomes given the characteristics of and competition
- 148 among variants, interactions with ongoing NPIs, and mass-vaccination. We thus use a multi-
- 149 variant, age-structured model to simulate potential pandemic outcomes for the period from
- 150 May 2021 to Aug 2021 under scenarios with different variant prevalence, NPIs, and vaccine

efficacy. We focus on NYC for which detailed data and estimates (e.g., contact patterns, variantprevalence, and vaccination rates) are available.

153

154 Fig 4A and Fig S4 show example projections of infections and mortality assuming a best-case 155 scenario in which vaccine-induced immunity is as effective against all three VOCs as for the 156 wild-type virus. At the time of these simulations (i.e., end of April 2021), the B.1.1.7 variant 157 was the predominant VOC in NYC; however, given their estimated propensity for immune 158 escape, both B.1.351 and P.1 could outcompete B.1.1.7 and become predominant in the 159 coming months (Fig 4A, top panel). The relative prevalence of B.1.351 and P.1 depends largely 160 on their initial introduction and establishment in the population. These two variants would 161 arise at similar rates and co-dominate, if they are introduced and established in the population 162 simultaneously (Fig 4A, left panel). However, should either be established in the population 163 ahead of the other, it would become dominant and suppress but not preclude the rise of the 164 other variant (Fig 4A, middle and right panels). In addition, the B.1.351 variant would be slightly more competitive if the vaccines are less effective against it than the P.1. variant (Fig 4B and 165 166 Table S1), as has been shown in laboratory studies<sup>7,9</sup>. 167

168 Tallies of model-projected infections (Fig 4B) and deaths (Fig S4) reveal four key determinants 169 of future pandemic outcomes. First, simultaneous introduction of both the B.1.351 and P.1 170 variants would lead to larger increases of infections and mortality than sole introduction of either variant (Fig 4B and Fig S4B). This result indicates the importance of limiting the 171 introduction of multiple VOCs. Second, maintaining very high vaccine efficacies against all 172 173 variants is critical for mitigating the risk of a large resurgence in populations with relatively high 174 vaccination coverage (e.g., compare the first three subplots in Fig 4B). Third, continued non-175 pharmaceutical preventive measures will reduce infection resurgence as municipalities reopen 176 economies. For instance, even with high vaccine efficacy, a rapid, full reopening before a very 177 large proportion of the population are fully vaccinated could lead to approximately three times 178 as many infections as when reopening occurs more slowly (Fig 4A and Fig 4B first subplot). Four, 179 reassuringly, while projected trends for COVID-19-related mortality are in general similar to those for infection (Fig S4A vs. Fig 4A), lower proportions of COVID-19-related deaths would 180 181 occur due to the increased transmission of B.1.351 and/or P.1 (Fig S4B vs. Fig 4B; note the 182 larger proportion of deaths due to B.1.1.7 than infections). This is due to the currently higher 183 vaccination coverage among older adults who have been prioritized for vaccination in NYC 184 similar to many other municipalities (see Table S4 for vaccination coverage by age group). This 185 finding emphasizes the importance of vaccine effectiveness against VOCs and of prioritizing 186 vulnerable populations for vaccination in order to prevent severe outcomes of COVID-19. 187

188 DISCUSSION

5

189 Despite vaccine availability, the future trajectory of the COVID-19 pandemic remains uncertain 190 due to the potential additional emergence and continued spread of multiple VOCs. To improve 191 understanding of future pandemic dynamics, here we have developed and applied a 192 comprehensive model-inference system to quantify key viral properties for three VOCs: B.1.1.7, 193 B.1.351, and P.1. Our estimates for the B.1.1.7 variant are consistent with detailed 194 epidemiological evidence (32.5 – 54.6% increase in transmissibility and minimal immune evasion estimated here vs. 30 – 50% increase in secondary attack rate based on contact tracing 195 data<sup>3,4</sup> and little immune evasion based on laboratory and real-world vaccination data<sup>5,6,15</sup>). Our 196 estimates of the level of immune evasion for the B.1.351 and P.1 variants are also consistent 197 198 with antibody neutralization data suggesting both variants can evade prior immunity induced by infection and vaccination, though to a larger extent for the B.1.351 variant.<sup>7,9</sup> Here we 199 provide joint quantification of immune escape and the change in transmissibility for both 200 201 variants. Overall, the model-inference system estimates and model simulations suggest that 202 both B.1.351 and P.1 are likely more competitive than the B.1.1.7 variant due to their greater 203 propensity for immune escape. These estimates are consistent with observations from Qatar<sup>15</sup> and Canada<sup>16</sup> showing that the proportion of infections caused by B.1.351 and/or P.1 increased 204 despite earlier introduction and dominance of B.1.1.7 in these populations. Therefore, in spite 205 206 of the current widespread prevalence of B.1.1.7 in Europe and North America, importation of 207 B.1.351 and/or P.1 to these regions could replace B.1.1.7 dominance and lead to a further 208 increase of infections by either B.1.351, P.1 or both variants. Mass-vaccination with highly 209 effective vaccines is thus crucial for mitigating the risk of future SARS-CoV-2 resurgence,

- 210 particularly as economies re-open.
- 211

212 Our model-inference system estimates substantial immune escape for both P.1 and B.1.351. 213 For P.1, the mean estimate is bounded by a very broad confidence interval; however, for 214 B.1.351 the uncertainty is more constrained and indicates greater confidence that a substantial 215 level of immune escape occurs. These latter findings are supported by vaccine clinical trial and real-world data. In particular, Shinde et al.<sup>13</sup> found a similar likelihood of COVID-19, mostly due 216 217 to B.1.351, among trial participants who were seropositive at enrollment (i.e., after the first wave) compared to those seronegative. Although potential differences in risk of exposure 218 219 among the two comparison groups may have somewhat biased this finding, substantial repeat and breakthrough infection occurred due to B.1.351. Further, recent data from Qatar<sup>15</sup> indicate 220 221 that individuals receiving the full dosing regimen of the Pfizer BNT162b2 mRNA vaccine are at 222 greater risk of breakthrough infection with the B.1.351 variant than B.1.1.7. Continued 223 monitoring of the severity of both repeat and breakthrough infections is needed to more fully 224 understand ongoing risks of VOCs to both health and economy. In addition, the Qatar study<sup>15</sup> 225 highlights the importance of full vaccination (i.e., administration of both doses for mRNA 226 vaccines), as participants gained little protection against severe illness after the first vaccine

- dose (vs. ~50% efficacy for B.1.1.7), even though full protection against severe illness was
- retained after two vaccine doses. It is thus likely critical that best vaccination protocols are
- followed in order to confer protection against variants with immune escape properties and that
- 230 potential waning of vaccine-induced immunity over time is monitored.
- 231
- In light of the spatial expansion of B.1.1.7, B.1.351, and P.1 and the potential emergence of
- 233 other new variants, vaccination is paramount for controlling the COVID-19 pandemic. It is
- 234 imperative that vaccine production, distribution, and administration proceed expeditiously,
- 235 particularly in resource-limited settings. Without effective global control of the pandemic,
- continued transmission of SARS-CoV-2 will give rise to additional new variants and pose new
- 237 threats to all. As vaccines are distributed and administered, a continuation of non-
- 238 pharmaceutical preventive measures is needed to minimize infections among the unvaccinated.
- As shown in our simulations, despite the relatively high vaccine coverage obtained to date in a
- 240 place like NYC, COVID-19 infections could resurge if such locations lift preventive measures
- 241 prematurely.
- 242
- 243 Due to a lack of sub-regional data, we used aggregated country-level data to estimate the
- 244 properties for the three VOCs. Our model-inference system also did not account for differences
- of disease severity and infection-detection rate among age groups, which may vary
- 246 substantially.<sup>17</sup> This model simplification may introduce uncertainty and bias to our estimates,
- 247 particularly for Brazil where country-level data may mask more intense transmission in
- subpopulations and may have led to underestimation of the transmissibility of P.1.
- 249 Nevertheless, validation using independent data, including for Brazil, indicates that the model-
- 250 inference system is able to closely capture pandemic dynamics and accurately estimate
- 251 cumulative infection rates (Fig 2). Further, because the model-inference system simultaneously
- accounts for population susceptibility, disease seasonality, NPIs, and vaccination, it is able to
- 253 specifically estimate changes related to a given new variant and closely matches available
- 254 epidemiological data (e.g., for B.1.1.7). The model simulations using these estimated
- characteristics further illustrate the relative competitiveness of the three VOCs and delineate
- key determinants of future infection outcomes. Overall, our findings point to the importance of
- 257 preventing the spread of the B.1.351 and P.1 variants, in addition to B.1.1.7, via continued NPIs,
- 258 prompt mass-vaccination of all populations, continued monitoring of vaccine efficacy, and
- 259 potentially updating vaccine formulations to ensure high efficacy.
- 260

# 261 **METHODS**

# 262 Data sources and processing

- 263 The model-inference system uses reported COVID-19 case and mortality data to capture
- 264 transmission dynamics, weather data to estimate disease seasonality, mobility data to

265 represent concurrent NPIs, and vaccination data to account for changes in population 266 susceptibility due to vaccination, for each of the three countries (i.e., the UK, South Africa, and 267 Brazil). Country-level daily COVID-19 case and mortality data came from COVID-19 Data 268 Repository of the Center for Systems Science and Engineering (CSSE) at Johns Hopkins 269 University;<sup>18,19</sup> we aggregated the data to weekly intervals until the week of 4/11/2021 but 270 excluded initial weeks with low case rates (<2 per million population). Hourly surface station 271 temperature and relative humidity came from the Integrated Surface Dataset (ISD) maintained 272 by the National Oceanic and Atmospheric Administration (NOAA) and are accessible using the 273 "stationaRy" R package.<sup>20,21</sup> We computed specific humidity using temperature and relative humidity per the Clausius-Clapeyron equation.<sup>22</sup> We then aggregated these data for all 274 275 weather stations in each country with measurements since 2000 and calculated the average for 276 each week of the year during 2000-2020. To compute the seasonal trend, we used a method 277 developed by Yuan et al.<sup>23,24</sup> which estimates the relative reproduction number based on 278 temperature and specific humidity (see details in Supplemental Information). Daily mobility 279 data were derived from Google Community Mobility Reports;<sup>25</sup> we aggregated all businessrelated categories (i.e., retail and recreational, transit stations, and workplaces) in all locations 280 in each country to weekly intervals. Daily vaccination data (for 1<sup>st</sup> and 2<sup>nd</sup> dose if applied) for 281 the UK were sourced from Public Health England;<sup>26</sup> and data for South Africa and Brazil were 282 obtained from Our World in Data.<sup>27,28</sup> 283

284

#### 285 Model-inference system

286 Contact tracing data capturing chains of transmission can be used to compute the secondary 287 attack rate and quantify changes in transmissibility due to a given new variant. Surveillance 288 data and laboratory viral characterization can be used to document and quantify levels of 289 immune evasion. Yet such detailed data are often not available, particularly for resource-290 limited settings. Given these circumstances, mathematical modeling that assimilates epidemic 291 surveillance data provides an attractive alternate means for estimating key epidemiological 292 properties of novel variants, including the transmission rate. However, joint estimation of the 293 transmission rate and population susceptibility, which is related to immune evasion, is 294 challenging, as both quantities can change for a new variant. This problem arises 295 mathematically because the product of these two quantities, rather than either individually, determines disease incidence – i.e., at any point in time, given the incidence, transmissibility 296 297 and susceptibility are not individually identifiable. Nevertheless, we posit that transmissibility 298 and susceptibility affect epidemic dynamics differentially over time, and, as such, data at 299 multiple time points can enable joint estimation. We thus design a model-inference system to 300 estimate the most plausible joint changes in these two quantities using commonly available 301 incidence and mortality time series.

302

303 The model-inference system is comprised of an epidemic model for simulating the transmission 304 dynamics of SARS-CoV-2 and a statistical inference method for estimating the model state 305 variables and parameters. The epidemic model is a susceptible-exposed-infectious-recovered-306 susceptible (SEIRS) construct that further accounts for two-dose vaccination. In addition, to 307 include the effects of public health interventions and disease seasonality, it further adjusts the 308 transmission rate each week using mobility data and the estimated seasonal trend based on climate conditions (see Eqn S3 in the Supplemental Information). The system then combines 309 310 the model-simulated (prior) estimates and observed case and mortality data to compute posterior estimates using the ensemble Kalman adjustment filter (EAKF).<sup>29</sup> We also apply a 311 technique termed space re-probing<sup>30</sup> that accommodates possible large changes mid-pandemic 312 to transmissibility and population susceptibility. Further, due to the challenge identifying these 313 314 two quantities individually, we ran the model-inference system, repeatedly and in turn, in order 315 to test 14 major combinations of changes in transmissibility and susceptibility (see details in 316 Supplemental Information). Briefly, depending on the hypothesized change, we restricted the EAKF update to a given related set of parameters or variables. For instance, for the hypothesis 317 318 that the new variant changes the transmissibility but does not evade immunity, the system only allows major adjustment to the transmission rate and the infectious period; for the hypothesis 319 320 that the new variant induces both changes, the system allows major adjustment to the 321 transmission rate, the infectious period, and population susceptibility. The system then selects 322 the run with the best performance based on the accuracy of model-fit, one-step ahead 323 prediction, and magnitude of changes to key state variables to identify the most plausible 324 combination of changes in transmissibility and level of immune evasion (see Supplemental 325 Information). To approximate the distribution of the system (including all model state variables 326 and parameters), we employed an ensemble of model replica (n = 500 here) and updated the 327 ensemble posterior each week using the EAKF. In addition, to account for model stochasticity, we repeated each model-inference simulation 100 times for each dataset, each with initial 328 329 parameters and variables randomly drawn from prior distributions (Table S2). Consequently, 330 model estimates are aggregated from 50,000 model runs in total.

331

#### 332 Estimation of variant-specific changes in transmissibility and level of immune evasion

The model decouples the impact of concurrent NPIs and disease seasonality from the transmission rate and infectious period (Eqn S3); as such, estimates for the latter two

parameters are variant-specific. We thus compute transmissibility as the product of the

- transmission rate and infectious period. To reduce uncertainty, we average transmissibility
- 337 estimates over the first pandemic wave (excluding the first three weeks when model estimates
- 338 are less accurate) for the wild-type SARS-CoV-2 virus; similarly, we average the transmissibility
- estimates over the period when the new variant is dominant. We identify this latter time period
- based on the transmissibility estimates: 1) For the UK (B.1.1.7) and South Africa (B.1.351), the

estimated transmissibility increased and plateaued within 10 weeks (see Fig 3); we thus used 341 342 the period from the week with the maximal transmissibility during the 10 weeks following its initial increase to the end of our study period (i.e., the week of 4/11/2021). However, for the 343 UK, we excluded the 3<sup>rd</sup> lockdown period when estimated transmissibility is lower, potentially 344 345 due to better awareness of B.1.1.7 and preventive measures taken at the time not fully 346 captured by the model. Of note, contact tracing data also indicate a lower increase of the secondary attack rate around that time: 25-40% during 11/30/20 – 1/10/21 (among 1,364,301 347 348 cases for this expanded analysis)<sup>4</sup> vs. 30-50% during 11/30 - 12/20/20 (among 386,805 cases).<sup>3</sup> 349 2) For Brazil (P.1), the estimated transmissibility increased more gradually (see Fig 3), we thus 350 instead used either the weeks identified per 1) or the last 8 weeks of our study period, 351 whichever with a longer time period, to ensure the robustness of estimation. We then 352 compute the average change in transmissibility due to a new variant as the ratio of the two

- averaged estimates (i.e., after: before the rise of the new variant).
- 354
- To quantify immune evasion, we record all time points inducing major EAKF adjustments to 355 356 posterior estimates of susceptibility, compute the change in immunity as  $\Delta$ Imm =  $S_{t+1} - S_t + i_t$ (with  $S_t$  as the susceptibility at time-t and  $i_t$  as the new infections occurring at time-t), and sum 357 358 over all  $\Delta$ Imm estimates to compute the total change in immunity due to the new variant. We 359 then compute the level of immune evasion as the ratio of the total change in immunity during the second wave to the model-estimated population immunity at the end of the first wave. This 360 361 ratio provides an estimate of the fraction of individuals previously infected who are susceptible 362 to re-infection with the new variant.
- 363

For both quantities, we report the mean and 95% CI based on the mean estimates from 100repeated model-inference runs.

366

## 367 Model validation using model-generated synthetic data

368 To test the accuracy of the model-inference system, we generated 10 synthetic datasets using a two-variant SEIRS model (see Eqn. S4) and different scenarios of changing transmissibility and 369 370 immune evasion (Table S3). In each scenario, a new variant was introduced at week 21 of the 371 simulation. We then combined the incidence and mortality due to both variants and added 372 noise drawn from a Poisson distribution to represent observational error. We then applied the 373 model-inference system to estimate the model variables and parameters for each synthetic 374 dataset, per the procedure described above for real data. For comparison with model-375 inference system estimates, we computed the true values of population susceptibility and 376 transmissibility over time as the weighted average of the two variants based on the relative 377 prevalence at each time point (i.e., each week).

378

#### 379 Model validation using independent data

- 380 To compare model estimates with independent observations not assimilated into the model-
- inference system, we identified four relevant datasets: 1) the REACT study, which measures the
- 382 prevalence of SARS-CoV-2 using PCR-testing of volunteers from the general public living in the
- 383 UK. At the time of this study, the REACT study has conducted 10 rounds of testing during
- 384 5/1/2020 3/30/2021 (n = 1,572,951 tests in total)<sup>10,11</sup>; Fig 2B plots our estimates of prevalence
- of SARS-CoV-2 each week, overlaying all 10 measures from the REACT study for corresponding
- time periods; 2) a serosurvey of workers in Cape Town, South Africa, conducted
- 387 during 8/17 9/4/2020 (n = 405 participants);<sup>12</sup> 3) serology tests among participants enrolled
- during 8/17 11/25/2020 in the Novavax NVX-CoV2373 vaccine phase 2a-b trial in South Africa
- 389 (n=1324).<sup>13</sup> Given this long enrollment period, we used the centered 2-week window (9/29 –
- 10/13/20) to match with our model estimates. and 4) two nationwide random household
- 391 serosurveys conducted in Brazil during 5/14 5/21/2020 (n = 25,025 participants) and 6/4 –
- 392 6/7/2020 (n = 31,165 participants).<sup>14</sup> To account for the delay in antibody generation, we
- 393 shifted the timing of each serosurvey 14 days when comparing to model-inference system
- 394 estimates of cumulative infection rates in Fig 2 D and E.
- 395

# Model simulations testing the relative competitiveness of VOCs and projecting future transmission dynamics.

Here we modified a multi-variant model previously developed for influenza virus<sup>31</sup> to include 398 age structure and interactions (Eqn. S5). The multi-variant model accounts for: 1) competition 399 400 between each pair of SARS-CoV-2 variants (e.g. wild-type and B.1.1.7) via cross-protective 401 immunity; 2) variant-specific transmissibility and population susceptibility, based on estimates 402 derived in this study; 3) variant-specific vaccine efficacy under different scenarios (see Table 403 S5); 4) age-specific differences in vaccination coverage at the start of simulation and vaccination uptake rates for the simulation period (see Table S4); 5) seasonality; and 6) changes 404 405 in NPIs under different scenarios (see Table S5). We used data from NYC for baseline vaccination coverage<sup>32</sup> and initial prevalence of different variants,<sup>33</sup> as well as key model 406 407 estimates (e.g., transmission rates and infection fatality risk by age group; see Table S5)<sup>17,34,35</sup>. As in previous work,<sup>17,34,35</sup> we included 8 age-groups (i.e. <1, 1-4, 5-14, 15-24, 25-44, 45-64, 65-408 409 74, and 75+ year-olds) in the model to account for age-specific differences. To focus on the three VOCs, we only included the B.1.1.7, B.1.351, and P.1 variants and attributed all other 410 411 variants as "wild-type" virus, even though at the start of the simulations, the B.1.526 variant 412 made up approximately one third of sequenced infections (N.b., the B.1.526 variant likely 413 emerged locally in NYC; we estimated a ~20% increase in transmissibility and nominal immune 414 evasion for this variant; based on these estimates the impact of this variant is expected to be 415 relatively minor). We did not account for potential differences in infection fatality risk by 416 variant, as such information is not available; therefore, the simulated mortality under different

- 417 scenarios only reflect the relative infection rate by age group, for which we apply age-specific
- 418 infection-fatality risk (see Table S5). In addition, due to uncertainty vis-à-vis the severity and
- 419 infection fatality risk among breakthrough infections (i.e., those who have been vaccinated), we
- 420 only show mortality-related simulations for the "Same VE" scenario which assumes no
- 421 reduction in VE.
- 422
- 423 Data Availability: All data used in this study are publicly available as described in the "Data
  424 sources and processing" section.
- 425
- 426 **Code availability:** All source code and data necessary for the replication of our results and 427 figures will be made publicly available.
- 428
- 429 Acknowledgements: This study was supported by the National Institute of Allergy and
- 430 Infectious Diseases (AI145883), the National Science Foundation Rapid Response Research
- 431 Program (RAPID; DMS2027369) and a gift from the Morris-Singer Foundation.
- 432
- 433 Author contributions: WY designed the study (main), conducted the model analyses,
- 434 interpreted results, and wrote the first draft. JS designed the study (supporting), interpreted
- 435 results, and critically revised the manuscript.
- 436
- 437 Competing interests: JS and Columbia University disclose partial ownership of SK Analytics. JS438 discloses consulting for BNI.

## 439 **References**:

- 4401Centers for Disease Control and Prevention. SARS-CoV-2 Variant Classifications and441Definitions, <<u>https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-</u>442surveillance/variant-info.html#Concern> (2021).
- Add National Collaborating Centre for Infectious Diseases. Updates on COVID-19 Variants of
   Concern, <<u>https://nccid.ca/covid-19-variants/</u>> (2021).
- 445 3 Public Health England. Investigation of novel SARS-CoV-2 variant, Variant of Concern
  446 202012/01, Technical briefing 3. (2020).
- 4474Public Health England. Investigation of novel SARS-CoV-2 variant, Variant of Concern448202012/01, Technical briefing 5. (2021).
- Wang, P. *et al.* Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. *Nature*,
  doi:10.1038/s41586-021-03398-2 (2021).
- 451 6 Planas, D. *et al.* Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to
  452 neutralizing antibodies. *Nat Med*, doi:10.1038/s41591-021-01318-5 (2021).
- 4537Hoffmann, M. *et al.* SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing454antibodies. *Cell* **184**, 2384-2393 e2312, doi:10.1016/j.cell.2021.03.036 (2021).

455	8	Zhou, D. et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and
456		vaccine-induced sera. <i>Cell</i> <b>184</b> , 2348-2361 e2346, doi:10.1016/j.cell.2021.02.037 (2021).
457	9	Garcia-Beltran, W. F. et al. Multiple SARS-CoV-2 variants escape neutralization by
458		vaccine-induced humoral immunity. Cell 184, 2372-2383 e2379,
459		doi:10.1016/j.cell.2021.03.013 (2021).
460	10	Riley, S. et al. REACT-1 round 10 report: Level prevalence of SARS-CoV-2 swab-positivity
461		in England during third national lockdown in March 2021. medRxiv,
462		2021.2004.2008.21255100, doi:10.1101/2021.04.08.21255100 (2021).
463	11	Riley, S. et al. Resurgence of SARS-CoV-2: detection by community viral surveillance.
464		<i>Science</i> , doi:10.1126/science.abf0874 (2021).
465	12	Shaw, J. A. et al. Higher SARS-CoV-2 seroprevalence in workers with lower
466		socioeconomic status in Cape Town, South Africa. <i>Plos One</i> <b>16</b> , e0247852,
467		doi:10.1371/journal.pone.0247852 (2021).
468	13	Shinde, V. <i>et al.</i> Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant.
469		N Engl J Med, doi:10.1056/NEJMoa2103055 (2021).
470	14	Hallal, P. C. et al. SARS-CoV-2 antibody prevalence in Brazil: results from two successive
471		nationwide serological household surveys. <i>Lancet Glob Health</i> 8, e1390-e1398,
472		doi:10.1016/S2214-109X(20)30387-9 (2020).
473	15	Abu-Raddad, L. J., Chemaitelly, H. & Butt, A. A. Effectiveness of the BNT162b2 Covid-19
474		Vaccine against the B.1.1.7 and B.1.351 Variants. New Engl J Med,
475		doi:10.1056/NEJMc2104974 (2021).
476	16	Jesse Tahirali & Liu, S. Tracking variants of the novel coronavirus in Canada,
477		<https: coronavirus="" health="" td="" tracking-variants-of-the-novel-<="" www.ctvnews.ca=""></https:>
478		<u>coronavirus-in-canada-1.5296141</u> > (2021).
479	17	Yang, W. et al. Estimating the infection-fatality risk of SARS-CoV-2 in New York City
480		during the spring 2020 pandemic wave: a model-based analysis. The Lancet. Infectious
481		<i>diseases</i> <b>21</b> , 203-212, doi:10.1016/S1473-3099(20)30769-6 (2021).
482	18	COVID-19 Data Repository by the Center for Systems Science and Engineering (CSSE) at
483		Johns Hopkins University, < <u>https://github.com/CSSEGISandData/COVID-19</u> > (2021).
484	19	Dong, E., Du, H. & Gardner, L. An interactive web-based dashboard to track COVID-19 in
485		real time. The Lancet. Infectious diseases 20, 533-534, doi:10.1016/S1473-
486		3099(20)30120-1 (2020).
487	20	lannone, R. <i>Package 'stationaRy'</i> , < <u>https://cran.r-</u>
488		<pre>project.org/web/packages/stationaRy/stationaRy.pdf&gt; (2020).</pre>
489	21	lannone, R. <i>stationaRy</i> , < <u>https://github.com/rich-iannone/stationaRy</u> > (2020).
490	22	Wallace, J. & Hobbs, P. Atmospheric Science: An Introductory survey. 2nd Edition edn,
491		(Academic Press, 2006).
492	23	Yuan, H., Kramer, S. C., Lau, E. H. Y., Cowling, B. J. & Yang, W. Modeling Influenza
493		Seasonality in the Tropics and Subtropics. PLoS Comput Biol In press (2021).
494	24	Yuan, H., Kramer, S. C., Lau, E. H. Y., Cowling, B. J. & Yang, W. Modeling Influenza
495		Seasonality in the Tropics and Subtropics. medRxiv, 2021.2002.2004.21251148,
496		doi:10.1101/2021.02.04.21251148 (2021).
497	25	Google Inc. Community Mobility Reports, < <u>https://www.google.com/covid19/mobility/</u> >
498		(2020).

499	26	PUblic Health England. Coronavirus (COVID-19) in the UK,
500		<https: coronavirus.data.gov.uk="" details="" download=""> (2020).</https:>
501	27	Data on COVID-19 (coronavirus) vaccinations by Our World in Data,
502		<a href="https://github.com/owid/covid-19-data/tree/master/public/data/vaccinations">https://github.com/owid/covid-19-data/tree/master/public/data/vaccinations</a> (2020).
503	28	Mathieu, E. et al. A global database of COVID-19 vaccinations. Nature Human Behaviour,
504		doi:10.1038/s41562-021-01122-8 (2021).
505	29	Anderson, J. L. An Ensemble Adjustment Kalman Filter for Data Assimilation. <i>Mon.</i>
506		Weather Rev. <b>129</b> , 2884-2903, doi:10.1175/1520-0493(2001)129<2884:aeakff>2.0.co;2
507		(2001).
508	30	Yang, W. & Shaman, J. A simple modification for improving inference of non-linear
509		dynamical systems. arXiv, 1403.6804 (2014).
510	31	Yang, W., Lau, E. H. Y. & Cowling, B. J. Dynamic interactions of influenza viruses in Hong
511		Kong during 1998-2018. PLOS Computational Biology <b>16</b> , e1007989,
512		doi:10.1371/journal.pcbi.1007989 (2020).
513	32	New York City Department of Health and Mental Hygiene. COVID-19: Data - COVID-19
514		<i>Vacccines</i> , < <u>https://www1.nyc.gov/site/doh/covid/covid-19-data-vaccines.page</u> > (2021).
515	33	New York City Department of Health and Mental Hygiene. COVID-19: Data - COVID-19
516		Virus Variants, < <u>https://www1.nyc.gov/site/doh/covid/covid-19-data-archive.page</u> >
517		(2021).
518	34	Yang, W., Kandula, S. & Shaman, J. Projections of COVID19 Epidemic Outcomes and
519		Healthcare Demands for New York City (NYC), < <u>https://github.com/wan-</u>
520		<pre>yang/COLUMBIA-COVID19-PROJECTIONS-FOR-NYC&gt; (2020).</pre>
521	35	Yang, W., Shaff, J. & Shaman, J. Effectiveness of non-pharmaceutical interventions to
522		contain COVID-19: a case study of the 2020 spring pandemic wave in New York City. J R
523		<i>Soc Interface</i> <b>18</b> , 20200822, doi:10.1098/rsif.2020.0822 (2021).
524		

# Table and figure captions

**Table 1.** Estimated changes in transmissibility and level of immune evasion. Numbers showmodel estimated mean (95% CI) from 100 model-inference runs.

**Fig 1.** Model-inference system validation using model-generated synthetic data with an infection-detection rate of 20%. (A) 5 sets of synthetic data (dots) and model-fits to each dataset; lines show mean estimates and surrounding areas show 50% (dark) and 95% (light) CrIs. (B) weekly model estimated transmissibility and population susceptibility; lines show mean estimates and surrounding areas show 50% (dark) and 95% (light) CrIs, compared to the true values (dots). (C) overall estimates of the change in transmissibility and immune evasion (boxes and whiskers show model estimated median, interquartile range, and 95% CI from 100 model-inference simulations) compared to the true values (dots).

**Fig 2.** Model-inference system fit to data for the three countries and validation using independent datasets. The left column shows the model fit to reported weekly case and mortality data for the UK (A), South Africa (C), and Brazil (D). Dots show the weekly number of

cases (in blue) and deaths (in red) per 1 million persons; boxes and whiskers show corresponding model estimates (mean, 50% and 95% CrIs). Grey shaded boxes indicate the timing of lockdowns or key periods of restricted activity; horizontal arrows indicate the timing of variant identification and vaccination rollout. The right column compares available, independent measurements to corresponding model estimates. Red dots and error bars show measured prevalence over 10 periods of time from the REACT study for the UK (B), cumulative infection rates from two serology studies in South Africa (D), and cumulative infection rates from two nationwide household serosurveys in Brazil (F). Blue lines and surrounding areas show model estimated mean, 50% (dark) and 95% (light) CrIs.

**Fig 3.** Key model-inference system estimates. Left column shows estimated real-time reproduction number *R*<sub>t</sub>, middle column shows estimated transmissibility, and right column shows estimated population susceptibility for each week during the study period, for the three countries. For comparison, estimated weekly infection rates are superimposed in each plot (right y-axis). Blue lines and surrounding areas show the estimated mean, 50% (dark) and 95% (light) CrIs. Boxes and whiskers show the estimated weekly infection rates (mean, 50% and 95% CrIs). Grey shaded areas indicate the timing of lockdowns or key periods of restricted activity; horizontal arrows indicate the timing of variant identification and vaccination rollout. *Note that the transmissibility estimates (middle column) have removed the effects of changing population susceptibility, NPIs, and disease seasonality; thus, the trends are more stable than the reproduction number (<i>R*<sub>t</sub>; left column) and reflect changes in variant-specific properties.


**Fig 4.** Model projections of infection, under different scenarios of VOC co-circulation, NPIs, and vaccine efficacy (VE). (A) Example projected epidemic trajectories for each variant assuming the VE is as high as for the wild-type virus. Lines and surrounding areas show model projected median and interquartile range (color-coded for each variant as indicated by the legend). (B) Tallies over the entire simulation period (May – Aug 2021) for different scenarios of seeding, VE (as indicated in the subtitles), and NPIs (as indicated by the x-axis labels). All numbers are scaled for 1 million people. For the projected percentages for each variant and uncertainty bounds, see Table S1.

Table


**Table 1.** Estimated changes in transmissibility and level of immune evasion. Numbers showmodel estimated mean (95% CI) from 100 model-inference runs.

		Changes in	
Location	Variant	Transmissibility (%)	Immune evasion (%)
United Kingdom	B.1.1.7	46.6 (32.3 <i>,</i> 54.6)	3.9 (0, 36.2)
South Africa	B.1.351	32.4 (14.6, 48)	61.3 (42.6, 85.8)
Brazil	P.1	43.3 (30.3, 65.3)	52.5 (0, 75.8)


**Fig 1.** Model-inference system validation using model-generated synthetic data with an infection-detection rate of 20%. (A) 5 sets of synthetic data (dots) and model-fits to each dataset; lines show mean estimates and surrounding areas show 50% (dark) and 95% (light) CrIs. (B) weekly model estimated transmissibility and population susceptibility; lines show mean estimates and surrounding areas show 50% (dark) and 95% (light) CrIs, compared to the true values (dots). (C) overall estimates of the change in transmissibility and immune evasion (boxes and whiskers show model estimated median, interquartile range, and 95% CI from 100 model-inference simulations) compared to the true values (dots).




**Fig 2.** Model-inference system fit to data for the three countries and validation using independent datasets. The left column shows the model fit to reported weekly case and mortality data for the UK (A), South Africa (C), and Brazil (D). Dots show the weekly number of cases (in blue) and deaths (in red) per 1 million persons; boxes and whiskers show corresponding model estimates (mean, 50% and 95% CrIs). Grey shaded boxes indicate the timing of lockdowns or key periods of restricted activity; horizontal arrows indicate the timing of variant identification and vaccination rollout. The right column compares available, independent measurements to corresponding model estimates. Red dots and error bars show measured prevalence over 10 periods of time from the REACT study for the UK (B), cumulative infection rates from two serology studies in South Africa (D), and cumulative infection rates from two nationwide household serosurveys in Brazil (F). Blue lines and surrounding areas show model estimated mean, 50% (dark) and 95% (light) CrIs.



**Fig 3.** Key model-inference system estimates. Left column shows estimated real-time reproduction number *R*<sub>t</sub>, middle column shows estimated transmissibility, and right column shows estimated population susceptibility for each week during the study period, for the three countries. For comparison, estimated weekly infection rates are superimposed in each plot (right y-axis). Blue lines and surrounding areas show the estimated mean, 50% (dark) and 95% (light) CrIs. Boxes and whiskers show the estimated weekly infection rates (mean, 50% and 95% CrIs). Grey shaded areas indicate the timing of lockdowns or key periods of restricted activity; horizontal arrows indicate the timing of variant identification and vaccination rollout. *Note that the transmissibility estimates (middle column) have removed the effects of changing population susceptibility, NPIs, and disease seasonality; thus, the trends are more stable than the reproduction number (<i>R*<sub>t</sub>; left column) and reflect changes in variant-specific properties.



**Fig 4.** Model projections of infection, under different scenarios of VOC co-circulation, NPIs, and vaccine efficacy (VE). (A) Example projected epidemic trajectories for each variant assuming the VE is as high as for the wild-type virus. Lines and surrounding areas show model projected median and interquartile range (color-coded for each variant as indicated by the legend). (B) Tallies over the entire simulation period (May – Aug 2021) for different scenarios of seeding, VE (as indicated in the subtitles), and NPIs (as indicated by the x-axis labels). All numbers are scaled for 1 million people. For the projected percentages for each variant and uncertainty bounds, see Table S1.



1	Supplemental Information
2	for
3	Epidemiological characteristics of three SARS-CoV-2 variants of concern and implications for
4	future COVID-19 pandemic outcomes
5	Wan Yang and Jeffrey Shaman
6	
7	1. Estimating seasonal trends
8	Many respiratory infections tend to occur seasonally and are predominantly prevalent during
9	certain months of the year (e.g., cold months in temperate climates). <sup>1</sup> This seasonal pattern has
10	been documented for influenza viruses, <sup>2</sup> respiratory syncytial viruses, <sup>3</sup> and endemic human
11	coronaviruses. <sup>4</sup> In addition, studies have showed that this seasonality may be associated with
12	climate conditions – particularly, temperature and humidity – as they may modulate the
13	survival and transmission of respiratory viruses. <sup>5-8</sup> For the SARS-CoV-2 virus, our work has also
14	shown that a winter-time seasonality exists, similar to endemic human coronaviruses in New
15	York City (NYC), and that models accounting for this seasonality enable more accurate
16	projection of COVID-19 pandemic dynamics than those do not. <sup>9,10</sup> However, to date, no
17	mechanistic models exist that quantify the response of the SARS-CoV-2 virus to temperature
18	and humidity and in turn the seasonality of COVID-19. In addition, seasonal trends may differ by
19	climate. For instance, epidemics of influenza can occur any time of the year in subtropical and
20	tropical climates; it is thus more difficult to characterize the seasonality of respiratory infections
21	in these climates. To address these challenges, we recently developed a flexible climate-forced
22	model of epidemic dynamics for subtropical and tropical climates; results with this model also
23	describe the response to temperature and humidity conditions common in temperate
24	climates. <sup>11,12</sup> Thus, to account for the potentially diverse seasonal trends of COVID-19 in the
25	UK (temperate climates), South Africa (mostly temperate climates), and Brazil (mostly tropical
26	climates), we applied this climate-forcing to temperature and humidity data for each country
27	and computed the relative seasonal trend for each country.
28	
29	Specifically, the climate-forcing takes the following form:
	m

$$R_0(t) = [aq^2(t) + bq(t) + c] [\frac{T_c}{T(t)}]^{T_{exp}}$$
[S1]

30 where  $R_0(t)$  is the basic reproduction number at time t; q(t) is specific humidity (i.e. a measure 31 of absolute humidity) at time t; and T(t) is temperature at time t. In essence, the forcing 32 function assumes that specific humidity has a bimodal effect on  $R_0$ , with both low and high 33 humidity conditions favoring transmission; in addition, this effect is moderated by temperature, 34 where low temperatures promote transmission and temperatures above a certain threshold 35 (i.e.,  $T_c$  in Eqn. S1) limit transmission. Further, to link the coefficients a, b, and c to humidity q

- 36 and  $R_0$ , Yuan et al.<sup>11,12</sup> reparametrized the forcing function by solving the parabola with a nadir
- 37 at  $(q_{mid}, R_{0max} R_{0diff})$  and maxima at both  $(q_{min}, R_{0max})$  and  $(q_{max}, R_{0max})$ , such that:
- 38

$$\begin{cases} a = \frac{-b}{q_{max} + q_{min}} \\ b = \frac{R_{0_{diff}}(q_{max} + q_{min})}{(q_{max} - q_{mid})(q_{min} - q_{mid})} \\ c = \left(R_{0_{max}} - R_{0_{diff}}\right) - aq_{mid}^2 - bq_{mid} \end{cases}$$
[52]

39

40 Yuan et al.<sup>11,12</sup> estimated the parameters  $R_{0max}$  (i.e., the maximum  $R_0$ ),  $R_{0diff}$  (i.e., the difference

- between the maximum and minimum  $R_0$ ),  $q_{min}$ ,  $q_{mid}$ , and  $q_{max}$  (i.e., the minimum, median, and
- 42 maximum specific humidity for the response),  $T_c$  (the threshold temperature) and  $T_{exp}$  (the
- 43 exponent in Eqn S1) for influenza in Hong Kong, a subtropical city, based on long-term epidemic
- 44 data collected therein during 1998 2018. Here we use their mean estimates for these
- 45 parameters and temperature and humidity data for each country (see main text and Fig S5) to
- 46 compute the seasonal trend for each country using Eqns. S1-2. However, as these parameters
- 47 were estimated for influenza, the outputs do not represent the actual  $R_0$  for the SARS-CoV-2
- 48 virus. Thus, we instead compute the *relative* seasonal trend, by scaling the weekly country
- 49 output from Eqn S1 by the country mean output, such that this scaled output provides a
- 50 *relative*, seasonality-related transmissibility for each week of the year (see results in Fig S2).
- 51 These relative estimates also decouple the seasonality-related and variant-specific
- 52 transmissibility (assuming no interaction; see below).
- 53

## 54 2. Model-inference system

- 55 The model-inference system developed for this study consists of an SEIRSV model to simulate 56 the transmission dynamics of SARS-CoV-2 and the ensemble Kalman adjustment filter (EAKF)<sup>13</sup>
- 57 to estimate the model state variables and parameters, based on case and mortality data. Here
- 58 we describe the model and the filtering method in detail.
- 59
- 60 2.1. Epidemic model.
- 61 The SEIRSV (susceptible-exposed-infectious-recovered-susceptible-vaccination) model uses the
- 62 following set of equations to simulate the transition of sub-populations between different
- 63 disease stages, while accounting for disease seasonality, concurrent non-pharmaceutical
- 64 interventions (NPIs), and vaccination:
- 65

$$\begin{pmatrix}
\frac{dS}{dt} = \frac{R}{L} - \frac{b_t e_t m_t \beta_t IS}{N} - \varepsilon - v_1(t) - v_2(t) \\
\frac{dE}{dt} = \frac{b_t e_t m_t \beta_t IS}{N} - \frac{E}{Z} + \varepsilon \\
\frac{dI}{dt} = \frac{E}{Z} - \frac{I}{D} \\
\frac{dR}{dt} = \frac{I}{D} + v_1(t) + v_2(t)
\end{cases}$$
[S3]

66

where S, E, I, R are the number of susceptible, exposed (but not yet infectious), infectious, and 67 recovered/deceased individuals, respectively; N is the population size. The parameter  $\varepsilon$ 68 represents travel-related importation of infections (nominally set to 1 per 20 days per 1 million 69 70 population, unless specified otherwise). To account for local seasonality,  $b_t$ , the estimated 71 relative seasonal trend for each country (see Section 1 above and Fig S2) is used to adjust the 72 relative transmission rate at time t. To account for concurrent NPIs, the term  $m_t$ , the relative 73 population mobility at time t (in this study, we use data from Google Community Mobility 74 Reports;<sup>14</sup> see main text and Fig S2), is used to adjust the transmission rate. In addition, as the 75 effectiveness of NPIs is unknown and variable, the model further includes a parameter,  $e_t$ , to scale NPI effectiveness at time t. For virus-specific characterization,  $\beta_t$  is the variant-specific 76 transmission rate at time t, Z is the latency period, D is the infectious period, and L is the 77 78 immunity period. Note that the parameters  $e_t$ ,  $\beta_t$ , Z, D, and L are estimated by the model-79 inference system as described below.

80

81 To incorporate changes in population susceptibility due to vaccination, the model accounts for

two-dose vaccination via  $v_1(t)$  and  $v_2(t)$ . Specifically,  $v_1(t)$  is the number of individuals

83 successfully immunized after the first dose of the vaccine and is computed using vaccination

data and vaccine efficacy for  $1^{st}$  dose (see detailed settings in Table S2). Similarly,  $v_2(t)$  is the

85 additional number of individuals successfully immunized after the second vaccine dose

86 (excluding those successfully immunized after the first dose).

87

88 2.2. Observation model.

89 We compute the model-simulated number of cases and deaths for each week using the model-

90 simulated infection rate, as done in Yang et al.<sup>10</sup> Specifically, we include 1) a time-lag from

91 infectiousness to detection (i.e., an infection being diagnosed as a case) – drawn from a gamma

92 distribution with a mean of  $T_m$  and standard deviation (SD) of  $T_{sd}$  days – to account for delays in

93 diagnosis and detection; 2) an infection-detection rate (*r*), i.e. the fraction of infections

94 (including subclinical or asymptomatic infections) reported as cases, to account for under-

95 detection; 3) a time-lag from infectiousness to death, drawn from a gamma distribution with a

96 mean of 14 days and a standard deviation of 10 days, empirically based on mortality data; and

4) an infection-fatality risk (IFR), i.e., the fraction of infections that die from COVID-19. To

- 98 compute the model-simulated number of new cases per week, we multiply the model-
- simulated number of new infections per day by the infection-detection rate, and further
- 100 distribute these simulated cases in time per the distribution of time-from-infectiousness-to-
- 101 detection. We then aggregate the daily lagged, simulated cases to weekly totals for model
- 102 inference (see below). Similarly, to compute the model-simulated deaths per week and account
- 103 for delays in time to death, we multiply the simulated-infections by the IFR and then distribute
- 104 these simulated deaths in time per the distribution of time-from-infectiousness-to-death, and
- aggregate these daily numbers to weekly totals. For each week, the infection detection rate (*r*),
- the mean  $(T_m)$  and standard deviation  $(T_{sd})$  of time-from-infectiousness-to-detection, and the
- 107 IFR are estimated based on weekly case and mortality data, along with other model
- 108 parameters.
- 109

# 110 2.3. Inference using the EAKF

- 111 At the end of each week, the inference system uses the EAKF to update the state variables and
- parameters based on model-generated prior estimates and case and mortality data. Briefly, the
- 113 EAKF uses an ensemble of model realizations (*n*=500 here), each with initial parameters and
- variables randomly drawn from a prior range (see Table S2). After model initialization, the
- system integrates the model ensemble forward in time for a week (per Eqn S3) *stochastically* to
- compute the prior distribution for each model state variable or parameter, as well as the
- 117 model-simulated number of cases and deaths for that week as described in Section 2.2. The
- system then combines the prior estimates with the observed case and death data for the same
- 119 week to compute the posterior per Bayes' theorem.<sup>13</sup> During this filtering process, the system
- 120 updates the posterior distribution of all model parameters and variables for each week.<sup>13</sup> As
- such, it is able to capture the time-varying changes in transmission dynamics including the
- 122 variant-specific transmission rate ( $\beta_t$ ) and infectious period (D) the two parameters that we
- 123 use to compute variant-specific transmissibility over time.
- 124

125 However, unlike previous studies using similar model-inference approaches, here we further modify the EAKF filtering process to test different potential combinations of changes in 126 127 transmissibility and immune escape. To enable this exploration of systemic changes (e.g. due 128 to the emergence of a new variant), we randomly replace a small fraction of ensemble 129 members (3-10%) using values randomly drawn from specified ranges. This technique, termed 130 space reprobing (SR), was developed in order to explore state space without corrupting 131 performance of the filter.<sup>15</sup> Specifically for this application, we apply SR to a given related set of 132 parameters/variables and restrict the EAKF update of non-related parameters/variables, for 14 133 different hypothesized behaviors. These hypothesized changes are as follows:

134

135	1)	Hypothesis 1 (minor changes in transmissibility, no immune escape): Large updates are
136		only allowed for the two transmissibility-related parameters $eta_t$ and D; to explore the
137		changes, the system applies SR to these two parameters using values drawn from prior
138		ranges 10-20% higher than the initial priors.
139	2)	Hypothesis 2 (major changes in transmissibility only, no immune escape): Similar to 1);
140		but to explore the changes, the system applies SR to $eta_t$ and ${\it D}$ using values drawn from
141		prior ranges 30-40% higher than the initial priors.
142	3)	Hypothesis 3 (minor immune escape only, no changes to transmissibility): Large updates
143		are only allowed for S, the population susceptibility, up to a total loss of 50% of the prior
144		immunity.
145	4)	Hypothesis 4 (major immune escape only, no changes to transmissibility): Large updates
146		are only allowed for S, the population susceptibility, up to a total loss of 95% of the prior
147		immunity.
148	5)	Hypothesis 5 (minor changes in transmissibility + minor immune escape): combining 1)
149		and 3) above.
150	6)	Hypothesis 6 (major changes in transmissibility + major immune escape): combining 2)
151		and 4) above.
152	7)	Hypothesis 7 (minor changes in transmissibility + major immune escape): combining 1)
153		and 4) above.
154	8)	Hypothesis 8 (major changes in transmissibility + minor immune escape): combining 2)
155		and 3) above.
156	9)	Hypothesis 9 (changes in both transmissibility and immune escape, no restriction on
157		magnitude of change): Large updates are allowed for $eta_t$ and $D$ as well as S. To explore
158		the changes, initial SR uses values drawn from prior ranges 10-20% higher than the
159		initial priors, and values up to 30-40% higher than the initial priors if the inference
160		system detects the prior continues to underestimate the observed cases and deaths
161		with the 10-20% initial increase in SR values. In addition, SR allows updates of S up to
162		95% of the prior immunity.
163		
164	То асс	ount for slower changes in overall population immunity (i.e., in the entire country) as the
165	new va	ariant gradually spreads to different sub-regions across a large geographic space, such as
166	in Braz	il, we also explore the fitting using the following five additional settings:
167		
168	10	) Hypothesis 10 (immune escape only and changes to overall population immunity occur
169		slowly over time): Large updates are only allowed for <i>S</i> , up to a total loss of 95% of the
170		prior immunity; however, SR is applied to a smaller fraction of ensemble members than
171		in 1)-9) such that changes in S occur gradually.

- 11) Hypothesis 11 (minor changes in transmissibility + minor immune escape; both occur 172 173 slowly over time): Large updates are allowed for  $\beta_t$  and D as well as S. Adjustment to S 174 is allowed as in 10) but up to only 50% of prior immunity. In addition, for 175 transmissibility, the system applies SR to  $\beta_t$  and D using values drawn from prior ranges 176 10-20% higher than the initial priors. 177 12) Hypothesis 12 (major changes in transmissibility + minor immune escape; both occur slowly over time): Similar to 11); however, for  $\beta_t$  and D, initial SR uses values drawn 178 179 from prior ranges 10-20% higher than the initial priors, and values up to 30-40% higher 180 than the initial priors if the inference system detects the prior continues to 181 underestimate the observed cases and deaths with the 10-20% initial increase in SR 182 values. 183 13) Hypothesis 13 (minor changes in transmissibility + major immune escape; both occur 184 slowly over time): Similar to the settings specified in 11) but adjustment to S is allowed 185 up to 95% of prior immunity. 14) Hypothesis 14 (major changes in transmissibility + major immune escape; both occur 186 187 slowly over time): Similar to settings specified in 12) but adjustment to S is allowed up 188 to 95% of the prior immunity. 189 190 We carry out the model-inference process for each of the 14 settings described above and for 191 each country dataset. We then select the most plausible hypothesis for each country based on 192 the following criteria: 1) model fitting to case and mortality data, as indicated by the relative 193 root-mean-squared-error (RRMSE) between the *posterior* estimates for the corresponding 194 variable (i.e. case rate or mortality rate) and data; 2) the accuracy of one-step ahead prediction, 195 as indicated by the RRMSE between the prior estimates for the corresponding variable (i.e. case 196 rate or mortality rate) and data; 3) the level of adjustment needed for two key variables, i.e., 197 infection rate and case rate, as indicated by the RRMSE between the prior and posterior 198 estimates for each variable; 4) a penalty on the number of variables needing SR adjustment; 199 and 5) a penalty on the frequency of SR adjustment. We combine all these metrics by weighting 200 them heuristically using the following set of weights: 0.27 for the two metrics in 1); 0.13 for the
- two metrics in 2), 0.03 for the two metrics in 3), and 0.07 for both 4) and 5). We also tested
  other sets of weights and found that higher weights should be given to 1) and 2) based on
  results from the synthetic testing where the 'true' values of the state variables and parameters
  are known; however, in general, the final results are similar if there are minor changes to these
- 205

weights.

- 206
- 207 To account for model stochasticity, we repeat each model-inference 100 times for each
- 208 dataset, each with initial parameters and variables randomly drawn from the prior distributions
- 209 (Table S2). Each model-inference tests the 14 hypotheses described above, selects the one with

- 210 the best performance (i.e. minimizing the combined metric described above), and outputs the
- estimates of the best-performing run. That is, the model estimates reported in the main text
- are aggregated from 100 best-performing model runs (each with 500 ensemble members and
- 213 totaling 50,000 individual model realizations).
- 214

## 215 **3. Model validation using model-generated synthetic data**

216 To test the accuracy of our model-inference system, we generate 10 synthetic datasets using a

- 217 separate multi-variant SEIRS model, similar to models developed in Yang et al.<sup>16</sup> and Gog &
- 218 Grenfell.<sup>17</sup> Within this model, variants can interact via cross-immunity, which protects a
- 219 portion of individuals with prior infection (i.e. polarized immunity) by reducing transmission.
- 220 Specifically, the model takes the following form:
- 221

$$\begin{cases} \frac{dS_i}{dt} = \frac{R_i}{L_i} - \sum_j \frac{b_t e_t m_t c_{ij} \beta_j S_j I_j}{N} - \varepsilon \\ \frac{dE_i}{dt} = \frac{b_t e_t m_t \beta_i S_i I_i}{N} - \frac{E_i}{Z_i} + \varepsilon \\ \frac{dI_i}{dt} = \frac{E_i}{Z_i} - \frac{I_i}{D_i} \\ \frac{dR_i}{dt} = \frac{I_i}{D_i} - \frac{R_i}{L_i} \end{cases}$$
[S4]

222

where N is the population size; S<sub>i</sub>, E<sub>i</sub>, I<sub>i</sub>, and R<sub>i</sub>, are, respectively, the numbers of susceptible, 223 224 exposed-but-not-yet infectious, infectious, and recovered individuals, with respect to variant-i 225 (here, the wild-type SARS-CoV-2 virus or a new variant);  $\beta_i$ ,  $D_i$ , and  $L_i$  are, respectively, the 226 transmission rate, mean infectious period, and mean immunity period, for variant-*i*; and  $c_{ij}$ 227 measures the strength of cross-immunity to variant-*i* conferred by infection with variant-*i* (e.g., 228 close to 0 if it is weak and  $c_{ii}=1$  for infection by the same variant). The parameter  $\varepsilon$  represents 229 travel-related importation of infections; to generate the synthetic data (i.e., "truths"), we set  $\varepsilon$ 230 to 1 per week for the first 5 weeks and 1 every 3 days for the rest of the first wave (here weeks 231 1-20); for the second wave, as transmission has been established locally, we set  $\varepsilon$  to 0 for 232 simplicity. The terms  $b_t$ ,  $m_t$ , and  $e_t$  are the same as in Eqn S3 and account for seasonality and 233 NPIs over time. For simplicity, we omit birth, death, and vaccination.

234

To generate the synthetic data (i.e., "truths"), we seed the Eq. S4 model with 2 infections of

- wild-type virus at the start of each simulation and 50 infections of a new variant at the start of
- 237 Week 21, for N = 1 million people; we run the model stochastically with a daily time-step from
- the week starting 3/1/2020 to the week starting 2/21/2021 (i.e. 52 weeks in total) using the
- parameters listed in Table S3. To compute the weekly number of cases and deaths, we use the

- same procedure as described in Section 2.2 above for each variant. We then combine the
- 241 case/mortality estimates for both variants, add random noises drawn from a Poisson
- 242 distribution to mimic observational error. The final noise-added weekly case and mortality time
- 243 series are then used as synthetic data for testing the model-inference system (described in
- 244 Section 2 above). To compare the posterior estimates of key parameters and variables (e.g.
- transmissibility and population susceptibility) from the model-inference system, we compute
- the true values of population susceptibility and transmissibility over time as the weighted
- 247 average of the two variants based on the relative prevalence during each week. Fig 1 and Fig S1
- show the 10 model-generated truths including cases, deaths, and the computed "true" values
- of population susceptibility and transmissibility for each week of the simulation.
- 250

# **4.** Multi-variant, age-structured model for simulation to test the relative competitiveness of

## 252 **VOCs and project future SARS-CoV-2 dynamics.**

- 253 We modify the multi-variant model in Eqn S4 to further include age structure and vaccination.
- 254 The inclusion of age structure here allows incorporation of age-specific parameters (e.g.,
- 255 transmission rate and infection-fatality risk) as well as age-specific vaccination coverage and
- rates. Specifically, this multi-variant, age-structured SEIRSV model takes the following form:

$$\begin{cases} \frac{dS_{i}^{A}}{dt} = \frac{R_{i}^{A}}{L_{i}^{A}} - \sum_{j} b_{t} e_{t} m_{t} c_{ij} \sum_{a} \frac{\beta_{j}^{Aa} S_{j}^{A} I_{j}^{a}}{N^{a}} - \varepsilon_{i} - v_{i,1}^{A}(t) - v_{i,2}^{A}(t) \\ \frac{dE_{i}^{A}}{dt} = \sum_{j} b_{t} e_{t} m_{t} c_{ij} \sum_{a} \frac{\beta_{j}^{Aa} S_{j}^{A} I_{j}^{a}}{N^{a}} - \frac{E_{i}^{A}}{Z_{i}^{A}} + \varepsilon_{i} \\ \frac{dI_{i}^{A}}{dt} = \frac{E_{i}^{A}}{Z_{i}^{A}} - \frac{I_{i}^{A}}{D_{i}^{A}} \\ \frac{dR_{i}^{A}}{dt} = \frac{I_{i}^{A}}{D_{i}^{A}} - \frac{R_{i}^{A}}{L_{i}^{A}} + v_{i,1}^{A}(t) + v_{i,2}^{A}(t) \end{cases}$$
[S5]

257

258 Model parameters in Eqn S5 are similar to those in Eqn S4, expect for those related to age,

- which are indicated by the superscripts. The vaccination model component is also similar to
- Eqn S3, but with age-stratification. However, the terms  $v_{i,1}^A(t)$  and  $v_{i,2}^A(t)$  are variant-specific,
- as indicated by the additional subscript *i*; that is, they additionally account for the reduction in vaccine efficacy against the new variants, based on scenario assumptions specified in Table S5.
- 263
- As an example, we simulate the transmission dynamics under different scenarios of variant
- 265 prevalence, vaccine efficacy, and NPIs for a city like NYC, from the week of 4/25/2021 to the
- week of 8/22/2021 (i.e., approximately May August 2021). We use data or estimates available
- 267 for NYC to initialize the parameters and state variables needed for model simulations. In
- addition, we use our model-inference estimates for the VOCs for related parameters and

variables. Specifically, as in previous work,<sup>9,10,18</sup> we include 8 age-groups (i.e. <1, 1-4, 5-14, 15-269 24, 25-44, 45-64, 65-74, and 75+ year-olds) to account for age-specific differences. To focus on 270 271 the three VOCs, here we only include the B.1.1.7, B.1.351, and P.1 variants and attribute the 272 rest as "wildtype" virus. NYC data on variant prevalence among tested infections during the 273 weeks of March – April 2021 are used to inform the initial range of seeding for each variant 274 (Table S5). Initial conditions for the state variables (e.g., susceptibility and SARS-CoV-2 prevalence) for each age group are taken from estimates $^{9,10,18}$  made for the week of 4/18/2021, 275 276 using detailed data (including case, mortality, COVID-19-related emergency visit, mobility, and 277 vaccination) during 3/1/2020 - 4/24/2021. For each age group, to compute the initial variant-278 specific population susceptibility  $(S_i)$  at the start of a simulation, we move the estimated 279 proportion with immune escape for variant *i* among those who have had prior infection with 280 the wild-type virus but have not been vaccinated back to the susceptible compartment. The 281 number of people losing vaccine-induced immunity is computed based on scenario assumptions 282 determining the reduction in vaccine efficacy (see scenarios in Table S5). 283 284 The cross-immunity settings, i.e., values of  $c_{ii}$ 's in Eqn S5, come from our posterior model-285 inference estimates of immune escape and are used for all age groups. To reduce uncertainty, 286 here we use the 80% CI estimates (see Table S5). For instance, as our model-inference estimate 287 of immune escape for B.1.351 has an 80% CI of 40.1 - 82.8%, we set  $c(B.1.351 \leftarrow wildtype)$ , the cross-immune protection against B.1.351 conferred by prior infection of the wildtype virus 288

relative to variant-specific immunity, to values drawn from a uniform distribution ranging from

290 0.172 to 0.599 (i.e. cross-immunity is set to the complement of estimated immune escape). We

set all c(wildtype  $\leftarrow$  new variant) to 1 – that is, we assume full cross-immune protection against

- the wild-type virus conferred by infection due to any VOC.
- 293

Similarly, the variant-specific transmission rates, i.e.  $\beta_i$ 's, come from our posterior model-

- 295 inference estimates of the relative transmissibility for each variant. For instance, as our model-
- inference estimate of transmissibility for B.1.351 is 18.5 45.7% (80% CI) higher than that of
- 297 the wildtype virus, we set  $\beta_{B.1.351}$  to 1.185 1.457 times of the estimate for  $\beta_{wildtype}$ . The same
- 298 scaling is applied to all age groups.
- 299

300 Due to a lack of information, we do not account for potential differences in infection fatality 301 risk by variant; therefore, the simulated mortality under different scenarios only reflect the 302 relative infection rate by age group, for which we apply age-specific infection-fatality risk (see 303 Table S5). In addition, due to the uncertainty of the infection fatality risk among breakthrough 304 infections (i.e., those who have been vaccinated), we only show mortality-related simulations 305 for the "Same VE" scenario which assumes no reduction in VE. 306


- 307 We run the model for each scenario 1000 times stochastically, with the parameters and initial
- 308 conditions randomly drawn from uniform distributions with ranges specified in Table S5.
- 309 Results are summarized from the 1000 model runs for each scenario.
- 310

## 311 References:

- Moriyama, M., Hugentobler, W. J. & Iwasaki, A. Seasonality of Respiratory Viral
   Infections. *Annu Rev Virol* 7, 83-101, doi:10.1146/annurev-virology-012420-022445
   (2020).
- 3152Tamerius, J. *et al.* Global influenza seasonality: reconciling patterns across temperate316and tropical regions. *Environ Health Perspect* **119**, 439-445, doi:10.1289/ehp.1002383317(2011).
- 318 3 Baker, R. E. *et al.* Epidemic dynamics of respiratory syncytial virus in current and future 319 climates. *Nat Commun* **10**, 5512, doi:10.1038/s41467-019-13562-y (2019).
- Kissler, S. M., Tedijanto, C., Goldstein, E., Grad, Y. H. & Lipsitch, M. Projecting the
  transmission dynamics of SARS-CoV-2 through the postpandemic period. *Science* 368,
  860-+, doi:10.1126/science.abb5793 (2020).
- 3235Tamerius, J. D. *et al.* Environmental predictors of seasonal influenza epidemics across324temperate and tropical climates. *PLoS Pathog* **9**, e1003194,325Li 10 1271 //
- 325 doi:10.1371/journal.ppat.1003194 (2013).
- Shaman, J. & Kohn, M. Absolute humidity modulates influenza survival, transmission,
  and seasonality. *Proc Natl Acad Sci U S A* **106**, 3243-3248, doi:10.1073/pnas.0806852106
  (2009).
- Shaman, J., Pitzer, V. E., Viboud, C., Grenfell, B. T. & Lipsitch, M. Absolute humidity and
  the seasonal onset of influenza in the continental United States. *Plos Biol* 8, e1000316,
  doi:10.1371/journal.pbio.1000316 (2010).
- 3328Yang, W. & Marr, L. C. Mechanisms by which ambient humidity may affect viruses in333aerosols. Appl Environ Microbiol **78**, 6781-6788, doi:10.1128/AEM.01658-12 (2012).
- Yang, W., Shaff, J. & Shaman, J. Effectiveness of non-pharmaceutical interventions to
   contain COVID-19: a case study of the 2020 spring pandemic wave in New York City. *J R Soc Interface* 18, 20200822, doi:10.1098/rsif.2020.0822 (2021).
- Yang, W. *et al.* Estimating the infection-fatality risk of SARS-CoV-2 in New York City
  during the spring 2020 pandemic wave: a model-based analysis. *The Lancet. Infectious diseases* 21, 203-212, doi:10.1016/S1473-3099(20)30769-6 (2021).
- Yuan, H., Kramer, S. C., Lau, E. H. Y., Cowling, B. J. & Yang, W. Modeling Influenza
  Seasonality in the Tropics and Subtropics. *PLoS Comput Biol* In press (2021).
- 34212Yuan, H., Kramer, S. C., Lau, E. H. Y., Cowling, B. J. & Yang, W. Modeling Influenza343Seasonality in the Tropics and Subtropics. *medRxiv*, 2021.2002.2004.21251148,244dei:10.1101/2021.02.04.21251148 (2021)
- doi:10.1101/2021.02.04.21251148 (2021).

345	13	Anderson, J. L. An Ensemble Adjustment Kalman Filter for Data Assimilation. Mon.
346		Weather Rev. <b>129</b> , 2884-2903, doi:10.1175/1520-0493(2001)129<2884:aeakff>2.0.co;2
347		(2001).
348	14	Google Inc. Community Mobility Reports, < <u>https://www.google.com/covid19/mobility/</u> >
349		(2020).
350	15	Yang, W. & Shaman, J. A simple modification for improving inference of non-linear
351		dynamical systems. arXiv, 1403.6804 (2014).
352	16	Yang, W., Lau, E. H. Y. & Cowling, B. J. Dynamic interactions of influenza viruses in Hong
353		Kong during 1998-2018. PLOS Computational Biology <b>16</b> , e1007989,
354		doi:10.1371/journal.pcbi.1007989 (2020).
355	17	Gog, J. R. & Grenfell, B. T. Dynamics and selection of many-strain pathogens. Proc Natl
356		Acad Sci U S A <b>99</b> , 17209-17214, doi:10.1073/pnas.252512799 (2002).
357	18	Yang, W., Kandula, S. & Shaman, J. Projections of COVID19 Epidemic Outcomes and
358		Healthcare Demands for New York City (NYC), < <u>https://github.com/wan-</u>
359		<pre>yang/COLUMBIA-COVID19-PROJECTIONS-FOR-NYC&gt; (2020).</pre>
360		

**Fig S1.** Model validation using model-generated synthetic data with an infection-detection rate set to 10%. (A) 5 sets of synthetic data (dots) and model-fits to each dataset; lines show mean estimates and surrounding areas show 50% (dark) and 95% (light) CrIs. (B) weekly model estimated transmissibility and population susceptibility; lines show mean estimates and surrounding areas show 50% (dark) and 95% (light) CrIs, compared to the true values (dots). (C) overall estimates of the change in transmissibility and immune evasion (boxes and whiskers show model estimated median, interquartile range, and 95% CI from 100 model-inference simulations) compared to the true values (dots).






Fig S2. Pandemic dynamics, mobility, and estimated seasonal trends in the three countries.

**Fig S3.** Other model estimates. Left panel shows the estimated infection-detection rate and right panel shows the estimated infection-fatality risk for each week during the study period for the three countries. For comparison, estimated weekly infection rates are superimposed in each plot (right y-axis). Blue lines and surrounding areas show model estimated mean, 50% and 95% CrIs. Boxes and whiskers show model-estimated weekly infection rates (mean, 50% and 95% CrIs). Grey shaded boxes indicate the timing of lockdowns or key period of restrictions; horizontal arrows indicate the timing of variant identification and vaccination rollout.





Fig S4. Model projections of COVID-19 related mortality under different scenarios of VOC cocirculation and NPI. Due to the uncertainty on the infection fatality risk among breakthrough infections (i.e., those who have been vaccinated), all simulations shown here assume no reduction in vaccine efficacy (VE). All numbers are scaled for 1 million people.



Current NPI Current NPI Fully open, fast Current NPI Fully open, slow Fully open, fast Fully open, slow Fully open, slow Fully open, fast 25% less 50°% less 50% less 50% less 25% less 25% less




Fig S5. Weekly average temperature and specific humidity for the three countries.

**Table S1**. Model-simulated prevalence of different variants under different scenarios. Numbers show the median (and interquartile range; all in percentage) of tallies over the entire simulation period (i.e. the week of 4/25/2021 to 8/22/2021) for each scenario, as specified in columns 1 (seeding of the B.1.351 and P.1 variant), 2 (NPI), and 3 (reduction on vaccine efficacy).

	=					
Seeding	NPI	VE	Wildtype	B.1.1.7	B.1.351	P.1
Equal seeding	Current NPI	Same VE	8.7 (8.1, 9.4)	65.4 (62.1, 67.9)	11.9 (9.8, 15)	13.2 (11.5, 15.2)
Equal seeding	Current NPI	High VE	7.7 (7.1, 8.3)	63.9 (60.2, 67)	13.3 (10.5, 17)	14.3 (12.4, 16.6)
Equal seeding	Current NPI	Median VE	7.6 (6.9, 8.3)	63.1 (59.5, 66.3)	13.7 (10.8, 17.6)	14.6 (12.6, 17)
Equal seeding	25% less	Same VE	5.7 (4.9, 6.5)	57.1 (51.4, 62.3)	15.9 (11.3, 21.8)	19.5 (15.9, 23.8)
Equal seeding	25% less	High VE	4.5 (3.8, 5.4)	52.6 (47, 59)	19 (12.8, 26.6)	20.9 (16.9, 26.4)
Equal seeding	25% less	Median VE	4.3 (3.5, 5.1)	50.2 (43.1, 56.8)	20.5 (13.9, 30)	22.2 (17.6, 27.2)
Equal seeding	50% less	Same VE	3.8 (3, 4.7)	48.2 (39.9, 54.8)	19.5 (12.5, 29.3)	25.5 (19.7, 32.3)
Equal seeding	50% less	High VE	2.8 (2.1, 3.5)	40.7 (32.2, 49.1)	24.3 (14.7, 37.4)	27.6 (21.4, 36)
Equal seeding	50% less	Median VE	2.5 (1.9, 3.3)	36.6 (28.2 <i>,</i> 45)	27.8 (16.2, 41.2)	28.7 (21.5, 37.5)
Equal seeding	Fully open, slow	Same VE	2.9 (2.2, 3.7)	40.5 (32.4, 49.8)	20.9 (13.1, 35.3)	28.9 (21.8, 38)
Equal seeding	Fully open, slow	High VE	2 (1.5, 2.7)	33.9 (25.5, 43.7)	24.8 (15.1, 41.5)	32.5 (24, 42.2)
Equal seeding	Fully open, slow	Median VE	1.8 (1.3, 2.4)	30.6 (22.6, 40)	30.6 (17, 46.3)	32.5 (23.1, 42.3)
Equal seeding	Fully open, fast	Same VE	1 (0.9, 1.3)	26.8 (20.4, 35.4)	30.1 (17.2, 45.5)	36.7 (26.3, 48)
Equal seeding	Fully open, fast	High VE	0.8 (0.6, 0.9)	22.4 (16.7, 30)	33.7 (20.4, 50.8)	38.3 (26.7, 50.1)
Equal seeding	Fully open, fast	Median VE	0.7 (0.6, 0.8)	19.5 (15, 26)	39.9 (24.1, 56.1)	36.8 (24.9, 48.9)
More P.1	Current NPI	Same VE	11.9 (11.1, 12.8)	71.5 (69.4, 73.5)	1.6 (1.2, 2.1)	14.6 (12.9, 16.7)
More P.1	Current NPI	High VE	10.8 (9.9, 11.6)	70.9 (68.5, 73.3)	1.7 (1.3, 2.4)	16.1 (13.9, 18.6)
More P.1	Current NPI	Median VE	10.6 (9.8, 11.5)	70.9 (68.1, 73.1)	1.9 (1.4, 2.5)	16.3 (14.1, 18.9)
More P.1	25% less	Same VE	8.2 (7.1, 9.4)	66 (61.6, 69.9)	2.4 (1.6, 3.5)	22.4 (18.4, 27.5)
More P.1	25% less	High VE	6.9 (5.8, 7.9)	63.6 (57.7, 68.2)	2.7 (1.7, 4.4)	26 (21.2, 31.9)
More P.1	25% less	Median VE	6.6 (5.6, 7.5)	62 (56.4, 66.5)	3.1 (1.9, 5.1)	27.3 (22.6, 33)
More P.1	50% less	Same VE	5.7 (4.6, 7)	58.6 (50.8, 64.8)	3 (1.7, 5)	31.1 (24.6, 39.6)
More P.1	50% less	High VE	4.4 (3.4, 5.4)	52.5 (44.6, 59.7)	3.9 (2 <i>,</i> 7.5)	36.5 (29.2, 45.7)

More P.1	50% less	Median VE	4.1 (3.2, 5.1)	49.7 (42.3, 56.9)	4.5 (2.3, 8.5)	39.3 (32.1, 47.4)
More P.1	Fully open, slow	Same VE	4.4 (3.4, 5.8)	53.3 (44.5, 60.5)	3.5 (1.8, 6.8)	36.8 (28.8, 46.1)
More P.1	Fully open, slow	High VE	3.2 (2.5, 4.2)	45 (36.8, 53.6)	4.4 (2.3, 8.8)	45 (35.7, 53.9)
More P.1	Fully open, slow	Median VE	3 (2.3, 3.9)	43 (34.3, 50.8)	4.9 (2.5, 10.3)	45.6 (36.1, 55.6)
More P.1	Fully open, fast	Same VE	1.6 (1.3, 2)	36.1 (28.6, 45.2)	5.1 (2.3, 10.8)	53.2 (43.8, 63.2)
More P.1	Fully open, fast	High VE	1.2 (1, 1.4)	30.9 (24.3, 39.2)	6.9 (3, 14.2)	56.7 (47.8, 66.2)
More P.1	Fully open, fast	Median VE	1 (0.9, 1.3)	27.8 (21.9, 35.4)	8.4 (3.9, 17.1)	58.8 (47.7, 67.4)
More B.1.351	Current NPI	Same VE	12.1 (11.3, 12.9)	72.5 (69.8, 74.8)	13.2 (10.9, 16.6)	1.8 (1.5, 2.2)
More B.1.351	Current NPI	High VE	10.9 (10, 11.8)	72.2 (68.7, 74.9)	14.6 (11.5, 18.6)	1.9 (1.5, 2.4)
More B.1.351	Current NPI	Median VE	10.6 (9.8, 11.5)	71.5 (67.6, 74.6)	15.5 (12.3, 19.8)	2 (1.6, 2.5)
More B.1.351	25% less	Same VE	8.4 (7.2, 9.6)	68.9 (62, 73.6)	19.3 (13.7, 27)	2.8 (2, 3.8)
More B.1.351	25% less	High VE	7 (5.9, 8.1)	66.9 (58.1, 72.6)	22.3 (15.6, 32.3)	3.2 (2.3, 4.5)
More B.1.351	25% less	Median VE	6.5 (5.4, 7.8)	62.9 (53.8, 70.5)	26.3 (17.5, 36.5)	3.3 (2.4, 4.7)
More B.1.351	50% less	Same VE	5.9 (4.7, 7.3)	62.7 (51.1, 70.5)	26.4 (17.1, 39.2)	4.1 (2.7, 6)
More B.1.351	50% less	High VE	4.5 (3.5, 5.8)	56.6 (43.7, 67.4)	32.4 (20.1, 46.9)	4.9 (3.3, 7.3)
More B.1.351	50% less	Median VE	4.1 (3, 5.3)	53 (39.6, 63.4)	36.8 (24.3, 52.5)	5 (3.2 <i>,</i> 7.6)
More B.1.351	Fully open, slow	Same VE	4.7 (3.5, 6.2)	58.2 (43.8, 68.5)	30.7 (18, 47)	4.9 (3.2, 7.6)
More B.1.351	Fully open, slow	High VE	3.4 (2.4, 4.6)	50 (35.9, 62.4)	38.5 (23.5, 56.1)	5.7 (3.5, 8.9)
More B.1.351	Fully open, slow	Median VE	3.1 (2.2, 4.2)	44.7 (30.9, 57.4)	43.6 (28.2, 61)	5.9 (3.3, 9.5)
More B.1.351	Fully open, fast	Same VE	1.7 (1.3, 2.3)	42.2 (28.6, 55.5)	44.4 (28.7, 63.1)	7.5 (4.4, 13.1)
More B.1.351	Fully open, fast	High VE	1.2 (1, 1.6)	34.4 (23, 48.2)	53.4 (35.1, 69.1)	8.2 (4.7, 13.7)
More B.1.351	Fully open, fast	Median VE	1.1 (0.8, 1.4)	29.2 (19.9, 41.9)	59.7 (42.1, 72.6)	7.7 (4.3, 13.2)

Parameter/ variable	Symbol	Prior range	Source/rationale
Initial exposed	<i>E</i> (t=0)	5 – 50 times (for the UK), 1 – 10 times (for South Africa), or 2.5 – 25 times (for Brazil) of the reported number of cases on the first week of simulation	Low infection-detection rate in first weeks; likely higher initial introduction for the UK due to more international travel per capita.
Initial infectious	/(t=0)	Same as for <i>E</i> (t=0)	
Initial susceptible	<i>S</i> (t=0)	99 – 100% of the population	Almost everyone is susceptible initially
Population size	Ν	N/A	Based on data
Variant-specific transmission rate	в	[0.5, 0.8] for the UK; [0.4, 0.7] for South Africa; [0.4, 0.8] for Brazil	Based on $R_0$ estimates of around 1.5-4 for SARS-CoV-2. <sup>1-3</sup> Slightly lower ranges are used for South Africa and Brazil, as initial testing showed that the priors tend to overestimate the observations.
Scaling of effectiveness of NPI	е	[0.5, 1.5]	Around 1, with a large bound to be flexible.

**Table S2**. Prior ranges for the parameters used in the model-inference system for the three countries.

Latency period	Ζ	[2, 5] days	Incubation period: 5.2 days (95% CI: 4.1, 7) <sup>1</sup> ; latency period is likely shorter than the incubation period
Infectious period	D	[2, 5] days	Time from symptom onset to hospitalization: 3.8 days (95% CI: 0, 12.0) in
			China, <sup>4</sup> plus 1-2 days viral shedding before symptom onset. We did not distinguish symptomatic/asymptomatic infections.
Immunity period	L	[730, 1095] days	Assuming immunity lasts for 2-3 years
Mean of time from viral shedding to diagnosis	T <sub>m</sub>	[5, 7] days for the UK, [5, 8] days for South Africa and Brazil	From a few days to a week from symptom onset to diagnosis/reporting, <sup>4</sup> plus 1-2 days of viral shedding (being infectious) before symptom onset. There may be a slightly longer delay for South Africa and Brazil.
Standard deviation (SD) or time from viral shedding to diagnosis	T <sub>sd</sub> f	[1, 3] days	To allow variation in time to diagnosis/reporting

Infection-	r	For the UK: starting from U[0.01, 0.15] at time 0 and	Large uncertainties; therefore, in general
detection rate		allowed to increase over time using space re-probing <sup>5</sup> with	
		values drawn from U[0.1, 0.24] starting at week 5 (the	bounds for space re-probing (SR). Note
		week of 3/29/2020), U[0.05, 0.2] during the summer (July	that SR is only applied to 3-10% of the
		<ul> <li>– Aug 2020), U[0.1, 0.3] starting Sep 2020, and U[0.15, 0.3]</li> </ul>	ensemble members and <i>r</i> can migrate
		starting Nov 2020.	outside either the initial range or the SR
		For South Africa: starting from U[0.01, 0.06] at time 0 and	ranges during EAKF update. Efforts were
		allowed to change over time using space re-probing <sup>5</sup> with	made in the UK to increase detection of
		values drawn from U[0.02, 0.08] starting at week 5 (the	infection; however, detection during the
		week of 4/12/2020).	summer of 2020 was likely lower because
		For Brazil: starting from U[0.01, 0.1] at time 0 and allowed	more infections at the time occurred
		to change over time using space re-probing <sup>5</sup> with values	among younger age groups with no or mild
		drawn from U[0.02, 0.1] starting at week 5 (the week of	symptoms. In South Africa, due to the
		4/12/2020).	younger age structure in the population,
			infection detection rates were likely lower.
			In Brazil, infection-detection rates were
			likely low throughout the pandemic.
Infection fatality		For the UK: starting from U[0.001, 0.015] at time 0 and	Based on previous estimates <sup>6</sup> but extend
risk (IFR)		allowed to change over time using space re-probing <sup>5</sup> with	to have wider ranges. Note that SR is only
		values drawn from U[0.0001, 0.003] during Jun – Sep 2020	applied to 3-10% of the ensemble
		when infections occurred mostly among younger ages,	members and IFR can migrate outside
		values drawn from U[0.0001, 0.005] during Oct – Dec	either the initial range or the SR ranges
		2020, and [0.0001, 0.006] during Jan – Apr 2021 to	during EAKF update.
		account for higher IFR for B.1.1.7.	
		For South Africa: starting from [0.0001, 0.003] at time 0	
		and allowed to change over time using space re-probing <sup>5</sup>	

	with values drawn from U[0.0001, 0.0015] during the week	K
	of 4/19/2020 to the week of 7/5/2020 when case fatality	
	risk was lower as computed from the data, values drawn	
	from U[0.0001, 0.002] starting the week of 12/13/2020	
	with the rise of B.1.351.	
	For Brazil: starting from U[0.001, 0.01] at time 0 and	
	allowed to change over time using space re-probing <sup>5</sup> with	
	values drawn from U[0.0001, 0.007] starting at week 5 (the	
	week of 4/12/2020), values drawn from U[0.0001, 0.0035]	
	during the week of 6/21/2020 to the week of 11/8/2020	
	when case fatality risk was lower as computed from the	
	data, values drawn from U[0.0001, 0.006] starting the	
	week of 1/3/2021 with the rise of P.1, and values drawn	
	from U[0.0001, 0.01] starting the week of 2/7/2021 when	
	the healthcare systems began to be overwhelmed.	
Vaccine efficacy	<u>For the UK</u> : VE = 85% fourteen days after the 1 <sup>st</sup> dose, and	During our study period (up to mid-April
(VE)	95% seven days after the 2 <sup>nd</sup> dose.	2021), the UK mostly used the Pfizer and
	<u>For South Africa</u> : VE = 60% fourteen days after the 1 <sup>st</sup>	later on Oxford/AstraZeneca vaccine, both
	dose; no 2 <sup>nd</sup> dose (for J&J vaccine).	shown to be highly effective against both
	For Brazil: VE = 45% fourteen days after the 1 <sup>st</sup> dose, and	the wildtype virus and B.1.1.7. South
	55% seven days after the 2 <sup>nd</sup> dose.	Africa mostly used the J&J vaccine with just
		one dose. Brazil mostly used the Sinovac
		and Oxford/AstraZeneca vaccines with
		relatively lower VE against P.1.

References:

1 Li, Q. *et al.* Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. *New Engl J Med*, doi:10.1056/NEJMoa2001316 (2020).

2 Wu, J. T., Leung, K. & Leung, G. M. Nowcasting and forecasting the potential domestic and international spread of the 2019nCoV outbreak originating in Wuhan, China: a modelling study. *Lancet*, doi:10.1016/S0140-6736(20)30260-9 (2020).

3 Li, R. *et al.* Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). *Science* **368**, 489-493, doi:10.1126/science.abb3221 (2020).

4 Zhang, J. *et al.* Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study. *The Lancet. Infectious diseases*, doi:10.1016/S1473-3099(20)30230-9 (2020).

5 Yang, W. & Shaman, J. A simple modification for improving inference of non-linear dynamical systems. *arXiv*, 1403.6804 (2014).

6 Verity, R. *et al.* Estimates of the severity of coronavirus disease 2019: a model-based analysis. *The Lancet. Infectious diseases*, doi:10.1016/S1473-3099(20)30243-7 (2020).

Truth	Settings
Wildtype- virus, same for all truths	$\beta$ = 0.65 per day; Z = 3.5 days; D = 3.5 days; L = 2.5 years; T <sub>m</sub> = 6 days; T <sub>sd</sub> = 2 days; IFR = 0.7%
Variant in Truth 1	Large outbreak during the first wave (See Figs 1 and S1). No increase in transmissibility (i.e. same $\beta$ and D as for the wildtype virus); 80% increase in immune escape. Other parameters same as the wildtype virus.
Variant in Truth 2	Large outbreak during the first wave (See Figs 1 and S1). 50% increase in transmissibility (i.e. $\beta$ = 0.65 x 1.5 = 0.975 per day); no immune escape. Other parameters same as the wildtype virus.
Variant in Truth 3	Large outbreak during the first wave (See Figs 1 and S1). 50% increase in transmissibility (i.e. $\beta$ = 0.65 x 1.5 = 0.975 per day); 80% increase in immune escape. Other parameters same as the wildtype virus.
Variant in Truth 4	Large outbreak during the first wave (See Figs 1 and S1). 25% increase in transmissibility (i.e. $\beta$ = 0.65 x 1.25 = 0.8125 per day); 40% increase in immune escape. Other parameters same as the wildtype virus.
Variant in Truth 5	Small outbreak during the first wave (See Figs 1 and S1). 50% increase in transmissibility (i.e. $\beta$ = 0.65 x 1.5 = 0.975 per day); no immune escape. Other parameters same as the wildtype virus.
Infection- detection rate	20% for results shown in Fig 1 and 10% for results shown in Fig S1.

Table S3. Parameters used to generate the synthetic data for model validation

**Table S4.** Cumulative vaccination coverage used in the multi-variant, age-structured model simulations. Baseline vaccination coverage (as of 4/24/2021) is based on data for NYC. Projected vaccination rates for the simulation period (from the week starting 4/25/2021 to the week ending 8/29/2021) are based on data 10 days preceding the simulation and assuming a cumulative vaccination uptake of 80%. Note that ages under 15 (i.e., <1, 1-4, 5-14 years) are combined in the same column as they were not eligible to receive the vaccines at the time of this study. In addition, the numbers are aggregated from neighborhood-level estimates and thus could slightly exceed the 80% total for some age groups when some neighborhoods had actual vaccination coverage above 80% at baseline.

Timo point	Vaccine	Vaccina	Vaccination coverage (%) by age group (in year)					
Time point	dose	0-14	15-24	25-44	45-64	65-74	75+	
Start of simulation:	1st dose	0	25.4	41.7	52.9	69	58.2	
4/24/2021	2nd dose	0	10.5	26.7	40.7	62.6	53.6	
End of simulation:	1st dose	0	70	76	79.1	80.6	76.8	
8/29/2021	2nd dose	0	65.4	73.4	78.7	80.3	74.5	

**Table S5**. Parameter settings for different scenarios to simulate and project the impact of different variants of concern. Initial conditions and parameters are randomly drawn from uniform distributions with lower and upper bounds as specified below, based on estimates for NYC made for the week of 4/18/2021 using data during 3/1/2020 - 4/24/2021. Numbers associated with the parameter names denote the corresponding age groups.

scenario:	variant	parameter	lower bound	upper		
Seeding/VE/NPI		-		bound		
Equal seeding	wildtype	Initial seeding (%)	45	61		
Equal seeding	B.1.1.7	Initial seeding (%)	35	45		
Equal seeding	B.1.351	Initial seeding (%)	2	5		
Equal seeding	P.1	Initial seeding (%)	2	5		
More B.1.351	wildtype	Initial seeding (%)	49.4	62.8		
More B.1.351	B.1.1.7	Initial seeding (%)	35	45		
More B.1.351	B.1.351	Initial seeding (%)	2	5		
More B.1.351	P.1	Initial seeding (%)	0.2	0.6		
More P.1	wildtype	Initial seeding (%)	49.4	62.8		
More P.1	B.1.1.7	Initial seeding (%)	35	45		
More P.1	B.1.351	Initial seeding (%)	0.2	0.6		
More P.1	P.1	Initial seeding (%)	2	5		
All	All	Travel-related importation, $\varepsilon_i$ 1 per 21 days, for the entire city (N = 8.4 million)				
Same VE	wildtype	VE = 85% fourteen days after the 1st dose and 95% seven days after the 2nd days				
Same VE	B.1.1.7	VE = 85% fourteen days after the days after the 2nd days	e 1st dose and 9	5% seven		
Same VE	B.1.351	VE = 85% fourteen days after the days after the 2nd days	e 1st dose and 9	5% seven		
Same VE	P.1	VE = 85% fourteen days after the days after the 2nd days	e 1st dose and 9	5% seven		
High VE	wildtype	VE = 85% fourteen days after the days after the 2nd days	e 1st dose and 9	5% seven		
High VE	B.1.1.7	VE = 85% x .95 = 80.75% fourteen days after the 1st dose and 95% seven days after the 2nd days				
High VE	B.1.351	VE = 85% x .80 = 68% fourteen days after the 1st dose and VE = 95% x .9 = 85.5% seven days after the 2nd days				
High VE	P.1	VE = 85% x .85 = 72.25% fourteen days after the 1st dose and VE = 95% x .95 = 90.25% seven days after the 2nd days				

				050/			
Median VE	wildtype	VE = 85% fourteen days after the 1st dose and 95% seven days after the 2nd days					
		, , ,	on dave after th	a 1st dasa and			
Median VE	B.1.1.7	$VE = 85\% \times .95 = 80.75\%$ fourte	•				
		VE = $95\% \times .95 = 90.25\%$ seven	•	•			
Median VE	B.1.351	VE = 85% x .70 = 59.5% fourteen days after the 1st dose and VE = 95% x .8 = 76% seven days after the 2nd days					
		VE = 85% x .8 = 68% fourteen c		-			
Median VE	P.1	= 95% x .9 = 85.5% seven days	•				
Current NPI	all variants	no further increase in transmis		1 y 5			
current in i		transmission rate increases by		) to 25% in			
25% less NPI	all variants	total		1025/0 m			
			5% per week ur	) to 50% in			
50% less NPI	all variants	transmission rate increases by 5% per week up to 50% in total					
		transmission rate increases by 5% per week up to fully					
Full reopen, slow	all variants	reopen (~85% of current level)					
		transmission rate increases by	10% per week ι	ıp to fully			
Full reopen, fast	all variants	reopen (~85% of current level)					
	wildtype	$\beta_{11}$ (per day, same below)	0.11	0.16			
	wildtype	β22	0.078	0.11			
	wildtype	β <sub>33</sub>	0.11	0.15			
	wildtype	β44	0.13	0.19			
	wildtype	β55	0.16	0.25			
	wildtype	β <sub>66</sub>	0.13	0.19			
	wildtype	β77	0.13	0.19			
	wildtype	β <sub>88</sub>	0.11	0.16			
	wildtype	β <sub>12</sub>	0.055	0.08			
	wildtype	β <sub>13</sub>	0.014	0.021			
	wildtype	β14	0.0057	0.0084			
	wildtype	β15	0.018	0.026			
	wildtype	β <sub>16</sub>	0.0082	0.012			
	wildtype	β17	0.0058	0.0085			
	wildtype	β <sub>18</sub>	0.004	0.0059			
	wildtype	β <sub>21</sub>	0.039	0.055			
	wildtype	β23	0.01	0.014			
	wildtype	β <sub>24</sub>	0.0041	0.0058			
	wildtype	β <sub>25</sub>	0.013	0.018			
	wildtype	β <sub>26</sub>	0.0059	0.0083			

wildtype	β27	0.0042	0.0059
wildtype	β <sub>28</sub>	0.0029	0.004
wildtype	β <sub>31</sub>	0.013	0.018
wildtype	β <sub>32</sub>	0.013	0.018
wildtype	β <sub>34</sub>	0.0066	0.0089
wildtype	β35	0.0087	0.012
wildtype	β <sub>36</sub>	0.0048	0.0066
wildtype	β <sub>37</sub>	0.0034	0.0046
wildtype	β <sub>38</sub>	0.0044	0.006
wildtype	β41	0.0073	0.011
wildtype	β42	0.0073	0.011
wildtype	β <sub>43</sub>	0.012	0.017
wildtype	β45	0.012	0.017
wildtype	β46	0.0089	0.013
wildtype	β47	0.0032	0.0046
wildtype	β <sub>48</sub>	0.0059	0.0086
wildtype	β51	0.075	0.12
wildtype	β <sub>52</sub>	0.075	0.12
wildtype	β <sub>53</sub>	0.061	0.096
wildtype	β54	0.048	0.076
wildtype	β <sub>56</sub>	0.046	0.073
wildtype	β57	0.028	0.043
wildtype	β <sub>58</sub>	0.027	0.042
wildtype	β <sub>61</sub>	0.04	0.058
wildtype	β <sub>62</sub>	0.04	0.058
wildtype	β <sub>63</sub>	0.033	0.047
wildtype	β <sub>64</sub>	0.039	0.056
wildtype	β <sub>65</sub>	0.04	0.058
wildtype	β67	0.044	0.064
wildtype	β <sub>68</sub>	0.04	0.058
wildtype	β <sub>71</sub>	0.024	0.035
wildtype	β72	0.024	0.035
wildtype	β73	0.017	0.025
wildtype	β <sub>74</sub>	0.0074	0.011
wildtype	β75	0.018	0.025
wildtype	β <sub>76</sub>	0.025	0.036
wildtype	β <sub>78</sub>	0.051	0.074

wildtype	β <sub>81</sub>	0.017	0.024
wildtype	β <sub>82</sub>	0.017	0.024
wildtype	β <sub>83</sub>	0.018	0.025
wildtype	β <sub>84</sub>	0.013	0.018
wildtype	β <sub>85</sub>	0.016	0.023
wildtype	β <sub>86</sub>	0.028	0.04
wildtype	β87	0.043	0.061
wildtype	Z <sub>1</sub> (days, same below)	3.3	4.3
wildtype	Z <sub>2</sub>	3.3	4.3
wildtype	Z <sub>3</sub>	3.4	4.4
wildtype	Z <sub>4</sub>	3.4	4.4
wildtype	Z <sub>5</sub>	3.5	4.4
wildtype	Z <sub>6</sub>	3.5	4.5
wildtype	Z <sub>7</sub>	3.4	4.5
wildtype	Z <sub>8</sub>	3.3	4.4
wildtype	$D_1$	3.1	4
wildtype	D <sub>2</sub>	3.1	4.1
wildtype	D <sub>3</sub>	3	4
wildtype	D <sub>4</sub>	3.3	4.2
wildtype	D <sub>5</sub>	3.2	4.2
wildtype	D <sub>6</sub>	3.3	4.2
wildtype	D <sub>7</sub>	3.5	4.4
wildtype	D <sub>8</sub>	3.3	4.3
wildtype	IFR <sub>1</sub>	7.70E-05	0.00012
wildtype	IFR <sub>2</sub>	7.60E-05	0.00013
wildtype	IFR <sub>3</sub>	7.70E-05	0.00012
wildtype	IFR <sub>4</sub>	7.60E-05	0.00013
wildtype	IFR <sub>5</sub>	0.00031	0.00049
wildtype	IFR <sub>6</sub>	0.0033	0.0047
wildtype	IFR <sub>7</sub>	0.018	0.023
wildtype	IFR <sub>8</sub>	0.056	0.069
B.1.1.7	Increase in transmission rate	0.403	0.5227
B.1.1.7	Immune escape	0	0.1
B.1.351	Increase in transmission rate	0.1849	0.457
B.1.351	Immune escape	0.4414	0.8281
P.1	Increase in transmission rate	0.3682	0.4945
P.1	Immune escape	0.3588	0.6683

B.1.1.7	Increase in transmission rate	0.403	0.5227
B.1.1.7	Immune escape	0	0.1
B.1.351	Increase in transmission rate	0.1849	0.457
B.1.351	Immune escape	0.4414	0.8281
P.1	Increase in transmission rate	0.3682	0.4945
P.1	Immune escape	0.3588	0.6683